3832

j. med. chem. 2006, 49, 3832-3849

discovery and optimization of  xxxd189xxx  sulfonamides as inhibitors of  xxxd2595xxx 
aminopeptidase-2: a structural basis for the reduction of albumin binding
george s. sheppard,* jieyi wang, megumi kawai, steve d. fidanze, nwe y. bamaung, scott a. erickson, david  xxxd2595xxx . barnes,
jason s. tedrow, lawrence kolaczkowski, anil vasudevan, david c. park, gary t. wang, william j. sanders,
robert a. mantei, fabio palazzo, lora tucker-garcia, pingping lou, qian zhang, chang h. park, ki h. kim, andrew petros,
edward olejniczak, david nettesheim, phillip hajduk, jack henkin, richard lesniewski, steven k. davidsen, and
randy l. bell
cancer research, global pharmaceutical research and development, abbott laboratories, department r47a, 100 abbott park road,
abbott park, illinois 60064
received january 30, 2006

 xxxd2595xxx  aminopeptidase-2 ( xxxg1400xxx ) is a novel target for cancer therapy. as part of an effort to discover
orally active reversible inhibitors of  xxxg1400xxx , a series of  xxxd189xxx  sulfonamides with micromolar
affinities for human  xxxg1400xxx  were identified using affinity selection by mass spectrometry (asms) screening.
these micromolar hits were rapidly improved to nanomolar leads on the basis of insights from protein
crystallography; however, the compounds displayed extensive binding to human  xxxg124xxx  and had
limited activity in cellular assays. modifications based on structural information on the binding of lead
compounds to both  xxxg1400xxx  and domain iii of albumin allowed the identification of compounds with
significant improvements in both parameters, which showed good cellular activity in both proliferation and
 xxxd2595xxx  processing assays.
introduction
 xxxd2595xxx  aminopeptidases are metalloenzymes responsible
for the removal of the n-terminal initiator  xxxd2595xxx  residue
of nascent proteins. humans have multiple  xxxd2595xxx  aminopeptidases.  xxxg1399xxx  and  xxxg1400xxx  represent related but distinct
enzymes found in the cytosol;1 in addition, a mitochondrial
aminopeptidase of uncertain function, structurally related to
 xxxg1399xxx , has recently been reported.2 the type i and type ii
 xxxd2595xxx  aminopeptidases seem to show similar substrate
preferences; however, they are not fully redundant because the
sirna depletion of either enzyme is reported to inhibit the
proliferation of human cells.3 although one article has questioned the conclusion based on sirna knockdown studies,4
multiple studies have demonstrated that  xxxg1400xxx  is the molecular
target of the antiangiogenic natural product fumagillin5 (1a,
chart 1) and its semisynthetic analogue 1b ( xxxd1330xxx ),6 which
irreversibly inactivate the enzyme by a covalent modification
of a histidine residue in the active site.7  xxxd2166xxx  derivatives,
such as 1b,8 1c (ppi-2458),9 and 1d (ckd-732)10 display
inhibitory activity in animal models of angiogenesis and tumor
growth, supporting the potential of  xxxg1400xxx  inhibition as an
approach to the treatment of cancer and other diseases with an
angiogenic component. reversible inhibitors of  xxxg1400xxx  such
as 2 ( xxxd1165xxx )11 have also demonstrated activity in animal
models of angiogenesis and tumor growth, as have nonselective
inhibitors of both  xxxg1399xxx  and  xxxg1400xxx  such  xxxd79xxx   xxxd1710xxx  (laf-389).12
efforts to identify reversible selective  xxxg1400xxx  inhibitors with
characteristics suitable for oral administration in humans by
affinity selection by mass spectrometry (asms) screening13 of
mn2+ metap214 led to the identification of  xxxd189xxx 
sulfonamides such as 4 and 5.15 as indicated in table 1,
compound 5 showed potent inhibition in a  xxxg1400xxx  enzyme
assay (ic50 ) 10 nm); however, it was only moderately active
in inhibiting the proliferation of the human fibrosarcoma-derived
* to whom correspondence should be addressed. tel: 847-937-8572.
fax: 847-935-5165. e-mail: george.s.sheppard@abbott.com.

cell line ht-1080 (ec50 ) 2.4 µm). the addition of physiological concentrations (40 mg/ml)16 of human  xxxg124xxx 
(hsa) produced significant shifts in potency in both assays
(table 1), indicating that protein binding in general and hsa
binding in particular were potentially problematic issues for this
structure class. compounds 4 and 5 were measured to be 99.7%
and 99.8%, respectively, protein bound in rat plasma.
compound design. hsa is a highly abundant plasma protein
that plays a central role in drug distribution and pharmacokinetics. albumin represents around 60% of the total plasma
protein with a typical concentration of 0.6 mm. hsa possesses
several binding sites and is capable of binding a wide range of
endogenous and exogenous molecules.16 to characterize the
nature and kinetics of binding, an nmr study was undertaken
on 4 using domain iii of albumin, which is reported to have a
high affinity for anionic aromatic compounds.17 initial studies
indicated high affinity binding to a specific site. a structure of
the complex was then obtained, shown in figure 1, indicating
the binding to what is termed site ii of albumin.17 compound
4 binds to the hydrophobic cavity of domain iii formed by
helices 1, 2, 3, 4, and 6. the aromatic rings of the ligand point
deep into the pocket and make multiple contacts with residues
i388 and n391 on alpha helix 1, f403, l407 r410, and y411
on alpha helix 2, v433 on alpha helix 3, and a449 and l453
on alpha helix 4. as seen in figure 1, these constraints bury
the ortho position of the benzene sulfonyl ring of the ligand in
a hydrophobic pocket of the protein. the carboxyl group of the
ligand is in close proximity to r410 and y411 of the protein
and, thus, sits in a position analogous to the carboxyl group of
 xxxd2681xxx  and  xxxd1882xxx  in their hsa domain iii ligand
complexes.18,19 this high affinity binding appears to be restrictive,20 that is, kinetically limiting to the amount of drug available
for distribution into cells. we, therefore, sought to modify our
lead structures to reduce the extent of binding to hsa.
a comparison of the nmr structure of 4 bound to domain
iii of albumin with the x-ray crystal structures of 4 and 5 bound
to  xxxg1400xxx  (figure 2) suggested a strategy for the disruption

10.1021/jm0601001 ccc: $33.50 © 2006 american chemical society
published on web 06/08/2006

 xxxd189xxx  sulfonamide  xxxg1400xxx  inhibitors

chart 1.  xxxg1400xxx  inhibitor structures

of the high affinity binding to hsa. substitution at the ortho
position of the arylsulfonamide moiety would project away from
the  xxxg1400xxx  protein into solvent and should, therefore, be
accommodated, whereas the corresponding space in the albumin
complex is occupied by hydrophobic residues. we, therefore,
reasoned that the addition of a positively charged functional
group such as a tertiary amine tethered to the ortho position on
the benzenesulfonyl portion of 5 would afford potent  xxxg1400xxx 
inhibitors with reduced affinity for hsa. because albumin is
able to undergo shifts to accommodate a variety of structures,
the simple addition of steric bulk at this position was less likely
to disrupt binding. this approach of rational design using
structural data on drug-hsa complexes has been previously
employed successfully for the reduction of protein binding to
 xxxd1882xxx  derivatives18 and bcl-2 inhibitors.21
results and discussion
as an initial approach, the addition of various amines through
an aminoalkyl tether was examined. compounds 10 were

journal of medicinal chemistry, 2006, vol. 49, no. 13 3833
table 1. structure and biological activity of  xxxd189xxx 
sulfonamide  xxxg1400xxx  inhibitors

a inhibition of the mn2+ form of human  xxxg1400xxx  as described in ref 14.
inhibition of the proliferation of ht-1080 cells as described in ref 23.
c the measurements were carried out in the presence of 40 mg/ml of human
 xxxg124xxx .
b

prepared by the routes shown in scheme 1. the hydrogenation
of commercially available methyl 2-hydroxy-1-naphthoate,
followed by triflate formation provided intermediate 6. the
desired amino functionality was introduced using benzophenone
imine as an ammonia synthon under the palladium-catalyzed
conditions developed by buchwald22 to provide 7, which was
treated with hcl in wet thf to provide hydrochloride salt 8.
sulfonylation with 2-fluorobenzenesulfonyl chloride provided

3834

journal of medicinal chemistry, 2006, vol. 49, no. 13

figure 1. binding mode of 4 to domain iii of human  xxxg124xxx 
determined by nmr spectroscopy. the protein side chains showing
noe interactions with the ligand are shown in green.

figure 2. binding mode of 4 and 5 to the active site of  xxxg1400xxx 
determined by protein crystallography. the atomic coordinates have
been deposited with the protein data bank ( xxxd1224xxx , 1yw8).

9a, which was subjected to microwave-assisted nucleophilic
aromatic substitution with concomitant ester hydrolysis under
the reaction conditions to provide compounds 10a-10ae. a
series of analogues of 10f, bearing additional substitution on
the benzenesulfonamide (10af-10an), were prepared by the
same route using the respective substituted arylsulfonyl chlorides. alternatively, the sulfonylation of 8 with 2-nitrophenylsulfonyl chloride followed by the reduction to provide 11b
allowed the synthesis of 10y. additional examples of tethered
tertiary amines 13 were accessed from the corresponding
secondary amines by reductive amination, followed by ester
hydrolysis. the compounds were tested for the inhibition of
the  xxxg1400xxx  enzyme, with and without the addition of 40 mg/
ml of hsa to the assay buffer, as well as the inhibition of the
proliferation of the human fibrosarcoma-derived cell line ht1080 (table 1).
as anticipated on the basis of the structural analysis discussed
above, the compounds generally retained enzyme inhibitory
values comparable to that of 5. although the introduction of
the amines led to 2-10-fold decreases in activity against the
enzyme, the compounds linked to protonatable amines displayed
a reduced shift in potency upon the addition of hsa to the assay.
activities in the proliferation assay were also improved relative
to that of 5 in most of the examples, in both the standard assay
format (containing 10% fetal bovine serum) and with the
addition of hsa. the importance of the amine protonation is
illustrated by the large hsa shifts for boc derivatives 10l and

sheppard et al.

 xxxd2595xxx , pyrrolidinone analogue 10ae, and the less basic heteroaromatic analogues 10aa-10ad. the introduction of larger hydrophobic groups surrounding the distal amine (e.g., 10t, 10u, 13b,
and 13d) led to larger potency shifts. smaller alkyl groups, such
as dimethyl and diethylamino, gave the best results. tether
length had only a modest effect, and 3-4 carbon atoms between
the nitrogen attached to the benzenesulfonyl moiety and the
tertiary amine was optimal. branching and cyclization into the
tether was well tolerated with the exception of the branching
adjacent to the anilino nitrogen (e.g., 10ap). substitution at other
positions of the benzenesulfonyl (10af-10an) led to decreased
activity.
having validated the approach of tethering a tertiary amine
to reduce hsa binding, we turned our attention to other
tethering strategies. amide (14), urea (15), and carbamate (16)
variants of the alkylamino tether were prepared from intermediate 11b (scheme 1). analogues linked via sulfide (18)-,
sulfoxide (19)-, and alkoxide (20)-containing tethers were
prepared from ortho-bromo intermediate 17 (scheme 1).
analogues tethered via carbon linkages were prepared as shown
in scheme 2. analogues linked through an amide carbonyl were
accessible through either coupling to acid 22 followed by ester
hydrolysis, or through the aminocarbonylation of aryl bromide
17. intermediate 17 also provided access to analogues linked
via alkenyl (24 and 25) and alkyl (28) linkers via palladiumcatalyzed coupling reactions. analogues 24 could be prepared
through coupling with the appropriate aminoalkylalkenyl stannanes or from allylic alcohol intermediates 27. in the latter
sequence, the protection of the sulfonamide nitrogen was
required to prevent intramolecular alkylation upon the activation
of the alcohol. a similar sequence (scheme 3) was used to
prepare the cyclopropylmethyl-linked analogue 32.
as indicated in table 2, z-alkenyl linked analogues 24
provided the compounds with the best activity. the x-ray
structure of analogue 24n bound to  xxxg1400xxx  (figure 3) when
overlaid with that of 5 illustrates that, as planned, the addition
of the tethered amine group did not alter the mode of binding
with the target. the addition of a 4-fluoro substituent on the
benzenesulfonyl group had no effect on  xxxg1400xxx  inhibition but
led to slight reductions in the hsa shift and improved the
activity in the proliferation assay. a z-propenyl link combined
with a diethylamino group provided the best activity in the
proliferation assay, with 24b showing the best activity.
most analogues in the study had similar activity against the
isolated enzyme, yet a range of activities in cellular assays
spanning approximately 1000-fold was observed. the increased
potencies achieved in cellular assays are attributed primarily to
reduced protein binding (the assay medium contains 10% fetal
bovine serum) and improved cell permeability, providing higher
effective concentrations at the intracellular target. a comparison
of the enzyme potencies in the presence of hsa does not
completely explain the difference in antiproliferative values,
suggesting additional influences on the cellular activities.
although cell permeability was not routinely measured, compounds bearing the tethered amine were observed to achieve
higher concentrations in cells. for example, the relative cytosolic
to extracellular concentrations of 5 measured in rat erythrocytes
after equilibration with 10 µm compound was 1.29, whereas
the corresponding value for 10f was 2.81. enhanced cell
permeability may, therefore, account for some of the enhanced
activity in the cellular assays. other factors such as additional
protein binding partners or differences in subcellular localization
may also be involved. although it is unlikely to be of
physiological relevance,14 the enzyme activity of key analogues

 xxxd189xxx  sulfonamide  xxxg1400xxx  inhibitors

journal of medicinal chemistry, 2006, vol. 49, no. 13 3835

scheme 1a

a (a) h 1500 psi, pd/c, meoh/h o, 60 °c; (b) tf o, pyridine, ch cl , -20 °c; (c) ph cdnh, cs co , pdoac , xantphos, dioxane, 100 °c; (d) hcl,
2
2
2
2 2
2
2
3
2
thf/h2o; (e) arso2cl, pyridine (method a); (f) diamine, et3n, ch3cn, microwave, 200 °c (method b); (g) h2, rani, meoh/etoac; (h) boc-homoprolinal,
hoac, pscnbh3, ch2cl2/meoh, 70 °c; (i) tfa, ch2cl2; (j) lioh, dioxane/h2o, microwave, 160 °c; (k) carbonyl compound, hoac, pscnbh3, dmf;
lioh, dioxane/h2o, microwave, 160 °c (method c); (l) clch2cocl, pyridine, ch2cl2; amine (method d); ( xxxd2595xxx ) triphosgene, pyridine, diamine, 70 °c; (n)
carbonyldiimidazole, thf, diamine; lii, pyridine, microwave, 150 °c (method e); (o) rsh or roh, nah, dmf; lii, pyridine, microwave, 150 °c (method
f); (p) 30% aq h2o2, hoac (method g).

against the co2+ form of  xxxg1400xxx  was examined and showed
that the analogues were again of similar potency to each other
but 100-fold weaker than the values measured against the mn2+
form (data not shown).
to confirm that the compounds were showing better activity
in the proliferation assay because of the more effective inhibition
of intracellular  xxxg1400xxx  rather than the addition of an off-target
effect, 46 compounds with a range of potencies from 15 to 0.006
µm in the ht-1080 proliferation assay were evaluated for their
ability to inhibit  xxxd2595xxx  processing in ht-1080 cells by
 xxxg1400xxx , using a previously described protocol (table 3).14 as
shown in figure 4, the correlation between potency in the two
assays was good, with an r2 value of 0.821. an analysis of a
larger and more structurally diverse set of compounds within
the  xxxd189xxx  sulfonamide series provided an even higher
correlation (r2 ) 0.927, data not shown), strongly supporting
the view that improvements in proliferation inhibition were
achieved by the inhibition of  xxxg1400xxx  enzyme activity in cells.
in summary, the use of detailed structural data on the binding
of lead compounds to both the  xxxg1400xxx  target and an anti-target,
hsa, allowed the achievement of a greater than 100-fold gain
of activity in cellular assays and substantial improvements in
compound accessibility in the presence of hsa, as measured
by potency shifts from the added protein in enzyme and cellular
assays. the in vivo evaluation of these improved compounds
in animal models of angiogenesis and tumor growth will be
reported in a separate publication.

experimental section
biological assays.  xxxg1400xxx  enzyme inhibition experiments,14
ht-1080 proliferation assays,23 and  xxxd2595xxx  processing measurements11 were carried out as reported in previous publications
from these laboratories and are described in the supporting
information.
protein structure determinations. nmr structure of hsa
domain iii. hsa domain iii (residues 381-585) was expressed
in escherichia coli and purified as previously described.24 uniformly 15n,13c-labeled samples were prepared with media containing 15nh4cl and [u-13c]glucose. nmr samples contained 1.0 mm
of hsa domain iii and 1.1 mm ligand in 50 mm phosphate buffer
(ph 7.5) in 100% d2o. spectra were acquired at 310 k on a bruker
drx600 or drx800 nmr spectrometer. protein resonance
assignments were made using earlier assignments18 and 13c/1h
tocsy and noesy spectra.25,26 noe distance restraints were
obtained from 3d 15n- and 13c-edited noesy or 3d 13cedited/filtered noesy spectra acquired with a mixing time of 80
ms.
structure calculations. a total of 36 intermolecular noes were
assigned between compound 1 and resonances of hsa domain iii.
the structures were calculated using this noe data to dock the
ligand into the crystal structure of the hsa- xxxd2681xxx  complex19
using the program cnx (msi, san diego).27 during docking, the
coordinates of the protein backbone were fixed. a square-well
potential (fnoe ) 50 kcal mol-1) was employed to constrain noederived distances. there were no noe violations greater than 0.2
å in the final structures. only covalent geometry, noe, torsion,
and repulsive terms were included in structure refinement.

3836

journal of medicinal chemistry, 2006, vol. 49, no. 13

sheppard et al.

scheme 2a

a (a) arso cl, pyridine (method a); (b) lioh, meoh/h o, 60 °c; (c) diamine, hatu, nmm, dmf (method h); (d) co 450 psi, diamine, pdcl dppf,
2
2
2
et3n, thf, 120 °c; lii, pyridine, microwave, 160 °c; (e) rchdchsnbu3, pd(ptbu3)2, toluene, 90 °c; lii, pyridine, microwave, 150 °c (method i); (f)
semcl, nah, thf; (g) hoch2chdchsnbu3, pd(ptbu3)2, toluene, 50 °c; (h) mscl, ipr2net, ch2cl2; amine; lii, pyridine, microwave, 150 °c (method
j); (i) rchdchsnbu3, pd(ptbu3)2, toluene, 90 °c; h2, pd/c, meoh; lii, pyridine, microwave, 150 °c (method k).

scheme 3a

a (a) memcl, nah, thf; (b) tributyl-(2-(hydroxymethyl)cyclopropyl)stannane, pd(ptbu ) , pd dba , toluene, 90 °c; (c) mscl, pyridine; (d) r nh, reflux;
3 2
2
3
2
(e) lii, pyridine, microwave, 160 °c.

general chemical procedures. unless otherwise indicated, all
reagents and solvents were obtained commercially and used as
received. microwave-assisted chemical reactions were carried out
using either a smith synthesizer single mode instrument purchased
from personal chemistry or a milestone microsynth multimode
instrument from milestone, inc.; comparable results were obtained
with both systems. nmr spectra were generally obtained on
general electric qe 300 or varian unity spectrometers with
chemical shifts (delta) reported relative to that of tetramethylsilane as
an internal standard. mass spectra were obtained on finnigan
ssq7000 instruments using desorptive chemical ionization (dci),
atmospheric pressure chemical ionization (apci) or electrospray
ionization (esi). elemental analyses were performed by robertson
microlit laboratories or quantitative technologies incorporated.
preparative hplc purifications were typically performed using a
waters symmetry c8 column (40 mm × 100 mm, 7 µm particle
size) using a gradient of 10% to 100% acetonitrile/0.1% aqueous
tfa over 12min (15min run time) at a flow rate of 70 ml/min.
2-hydroxy-5,6,7,8-tetrahydronaphthalene-1-carboxylic acid
methyl ester. a steel autoclave was charged with 2-hydroxynaphthalene-1-carboxylic acid methyl ester (50.0 g, 248 mmol),
1000 ml of methanol, 100 ml of water, and 25.0 mg of 50 wt
%/wt pd/c. the reaction vessel was pressurized with hydrogen to
1500 psi and stirred at 60 °c for 2.5 h. the slurry was filtered to
remove the palladium catalyst. concentration of the solution in
vacuo provided an emulsion. toluene (500 ml) was added, and
the mixture further concentrated in vacuo. toluene (500 ml) was

added, the aqueous layer was drained off, and the mixture was
concentrated and then chase distilled with 2 × 500 ml of toluene.
the crude product was then purified by silica gel chromatography
(hexanes/ethyl acetate) to provide 35.8 g of the desired product
(70%). 1h nmr (400 mhz, cdcl3) delta 10.87 (s, 1 h), 7.13 (d, j )
8.56 hz, 1 h), 6.79 (d, j ) 8.56 hz, 1 h), 3.96 (s, 3 h), 2.99 ( xxxd2595xxx ,
2 h), 2.73 ( xxxd2595xxx , 2 h), 1.75 ( xxxd2595xxx , 4 h).
2-trifluoromethanesulfonyloxy-5,6,7,8-tetrahydronaphthalene1-carboxylic acid methyl ester (6). a 2 l round-bottomed flask
was charged with 35.0 g (169.7 mmol) of 2-hydroxy-5,6,7,8tetrahydronaphthalene-1-carboxylic acid methyl ester, dichloromethane (500 ml), and pyridine (35.6 ml, 441.2 mmol). the
mixture was cooled to an internal temperature of -20 °c.
trifluoromethanesulfonic anhydride (35.0 ml, 203.6 mmol) was
added dropwise over approximately 20 min. the mixture was
maintained at -20 °c for 15 min and warmed to ambient
temperature over 1 h. methyl-tert-butyl ether (1 l) was added, and
the reaction mixture was stirred 10 min and then filtered. the filtrate
was washed with 2 × 300 ml of 2 n hcl, 300 ml of water, and
300 ml of saturated aqueous  xxxd3213xxx  solution. the organics
were dried over  xxxd2534xxx  and concentrated in vacuo to a pink oil
(55.02 g, 96% yield). the product was used directly in the next
reaction. 1h nmr (400 mhz, cdcl3) delta 7.21 (d, j ) 8.64 hz, 1
h), 7.07 (d, j ) 8.51 hz, 1 h), 3.95 (s, 3 h), 2.81 ( xxxd2595xxx , 4 h), 1.831.79 ( xxxd2595xxx , 4h).
2-(benzhydrylidene-amino)-5,6,7,8-tetrahydronaphthalene-1carboxylic acid methyl ester (7). a 2 l round-bottomed flask

 xxxd189xxx  sulfonamide  xxxg1400xxx  inhibitors

journal of medicinal chemistry, 2006, vol. 49, no. 13 3837

table 2. structure and biological activity of  xxxd189xxx 
sulfonamide  xxxg1400xxx  inhibitors

figure 3. binding mode of 5 and 24n to the active site of  xxxg1400xxx 
determined by protein crystallography. the atomic coordinates have
been deposited with the protein data bank (1yw8, 1yw9).

a inhibition of the mn2+ form of human  xxxg1400xxx  as described in ref 14.
inhibition of the proliferation of ht-1080 cells as described in ref 23.
c the measurements were carried out in the presence of 40 mg/ml of human
 xxxg124xxx .
b

(equipped with thermocouple, overhead stirring and a nitrogen inlet)
was charged with cesium carbonate (74.1 g, 227.6 mmol), palladium(ii) acetate (730 mg, 3.25 mmol), and 4,5-bis-diphenylphosphanyl-9,9-dimethyl-9h-xanthene (xantphos, 2.82 g, 4.88
mmol). the flask was evacuated and backfilled with nitrogen 3×.
dioxane (300 ml) was added followed by another set of three
cycles of evacuation and backfilling with nitrogen. the canaryyellow slurry was stirred at room temperature for 10 min, and
triethylamine (0.68 ml, 4.877 mmol) was added. continued stirring

for 10 min at room temperature gradually changed the color from
yellow to red. 2-trifluoromethanesulfonyloxy-5,6,7,8-tetrahydronaphthalene-1-carboxylic acid methyl ester (55.0 g, 162 mmol) and
benzophenone imine (32.7 ml, 195.1 mmol) were added in 200
ml of dioxane via a cannula (50 ml wash). the reaction mixture
was warmed to an internal temperature of 100 °c for 4 h. cooling
the reaction mixture to ambient temperature was followed by
pouring the slurry into 1000 ml of ethyl acetate. the organics were
washed with 2 × 500 ml of water, and the ethyl acetate solution
was concentrated in vacuo. the mixture was chase distilled with 3
× 600 ml of methanol and adjusted to a final methanol volume of
600 ml. the red slurry was warmed to reflux for 30 min and then
cooled to ambient temperature. subsequent stirring for 2 h was
followed by filtration and washing of the yellow crystals with 2 ×
100 ml of methanol. the solid was dried in vacuo (>30 mmhg,
60 °c, 12 h) to provide the title compound as bright yellow crystals
(54.06 g, 90%). 1h nmr (400 mhz, cdcl3) delta 7.74 ( xxxd2595xxx , 2 h),
7.35 ( xxxd2595xxx , 8 h), 6.75 (d, j ) 8.10 hz, 1 h), 6.14 (d, j ) 8.10 hz,
1 h), 3.82 (s, 3 h), 2.69 ( xxxd2595xxx , 4 h), 1.75 ( xxxd2595xxx , 4 h).
2-amino-5,6,7,8-tetrahydronaphthalene-1-carboxylic acid
methyl ester hydrochloride (8). a 2 l three-necked roundbottomed flask was charged with 2-(benzhydrylidene-amino)5,6,7,8-tetrahydronaphthalene-1-carboxylic acid methyl ester (54.0,
146.2 mmol) and 550 ml of tetrahydrofuran. aqueous hydrochloric
acid (2.0 n, 225 ml) was added, and the reaction mixture was
stirred at ambient temperature for 1 h. the mixture was neutralized
with saturated aqueous potassium carbonate solution (until >ph
10) and then poured into 500 ml of ethyl acetate. a thick slurry
formed, whereupon 100 ml of saturated potassium carbonate was
added to form two distinct layers. the layers were separated, and
the aqueous solution was back-extracted with ethyl acetate (200
ml). the combined extracts were washed with 250 ml of saturated
aqueous  xxxd3213xxx  solution (250 ml) and dried over
anhydrous sodium sulfate. the organics were filtered and concentrated in vacuo to a dark yellow oil. the oil was diluted with
isopropyl acetate (1.1 l) and transferred to a 2 l three-necked
round-bottomed flask (equipped with an addition funnel, overhead
stirrer, and nitrogen line). a hydrogen chloride solution in dioxane
(4.0  xxxd2595xxx , 40.2 ml, 160.8 mmol) was added slowly via an addition
funnel over a period of 30 min whereupon a thick colorless slurry
formed. the mixture was stirred for additional period of 1 h and
then filtered, washed with 2 × 300 ml of isopropyl acetate, and
dried in vacuo (>30 mmhg, 50 °c, 12 h) to provide 5 as a white
solid (36.0 g, 100%). 1h nmr (400 mhz, dmso-d6) delta 8.0-9.0
(br s 3h), 7.15 ( xxxd2595xxx , 1 h), 6.99 (d, j ) 8.31 hz, 1 h), 3.82 (s, 3 h),
2.68 ( xxxd2595xxx , 4 h), 1.67 ( xxxd2595xxx , 4 h).
method a. methyl 2-{[(2-fluorophenyl)sulfonyl]amino}5,6,7,8-tetrahydro-1-naphthalenecarboxylate (9a). a solution of
8 (6.2 g, 25.7 mmol) in pyridine (70 ml) was treated with
2-fluorobenzenesulfonyl chloride (5.09 g, 26.2 mmol), stirred
overnight at room temperature, concentrated by rotary evaporation,

3838

journal of medicinal chemistry, 2006, vol. 49, no. 13

sheppard et al.

table 3. proliferation and  xxxd2595xxx  processing inhibition in ht-1080
cells by sulfonamide  xxxg1400xxx  inhibitors

compd

proliferation
ec50
(µm)a

cellular
 xxxg1400xxx 
ec50
(µm)b

5
10a
10b
10c
10d
10e
10f
10h
10n
10o
10p
10r
10s
10t
10u
10v
10w
10x
10y
10ao
10ap
13a
13c
13e
13f
14d
14e
15b
15e
15f
16
18b
19a
19b
20b
23a
23e
23f
23g
24a
24b
24c
24d
25a
25b
28c

2.4
1.3
0.54
0.64
2.2
0.19
0.14
0.61
0.16
0.41
0.51
0.085
0.096
1.6
15
0.29
0.38
0.46
0.14
0.46
0.21
0.95
0.5
0.35
0.13
0.43
0.48
2.8
2.5
0.77
0.83
0.52
0.27
0.11
6.2
0.52
1.2
0.12
2.6
0.019
0.006
0.049
0.033
0.29
0.17
0.068

9.6
1.9
0.62
0.27
1.5
0.46
0.15
0.13
0.21
0.4
0.098
0.091
0.065
0.51
18
0.069
0.11
0.052
0.11
0.066
0.12
1
0.095
0.27
0.22
0.8
0.24
1.9
2.2
0.38
0.68
0.66
0.36
0.023
5.1
0.35
1.1
0.26
6.4
0.023
0.0053
0.056
0.12
3
0.39
0.12

a inhibition of the proliferation of ht-1080 cells as described in ref 23.
inhibition of  xxxd2595xxx  processing by  xxxg1400xxx  in ht-1080 cells as
described in ref 11.

b

and the residues shaken in a separatory funnel with 1 n hcl and
etoac. the organic phase was washed with brine, dried ( xxxd2534xxx ),
filtered, and concentrated to give 8.56 g of the crude product, which
was slurried in 25 ml of hot etoac. hexanes (75 ml) were added
and the mixture cooled and filtered to provide 8.03 g (86%) of the
title compound as orange needles. ms (esi(+))  xxxd2595xxx /e 364 ( xxxd2595xxx  +
h)+; (esi(-))  xxxd2595xxx /e 362 ( xxxd2595xxx  - h)-; 1h nmr (300 mhz, dmsod6) delta 7.64 ( xxxd2595xxx , 2h), 7.38 (dt, 1h), 7.28 (dt, 1h), 7.02 (d, 1h), 6.90
(d, 1h), 3.64 (s, 3h), 2.65 (br s, 2h), 2.51 (br s, 2h), 1.67 (br s,
4h).
methyl 2-{[(2,6-difluorophenyl)sulfonyl]amino}-5,6,7,8-tetrahydro-1-naphthalenecarboxylate (9b). the title compound was
prepared from 8 and 2,6-difluorophenylsulfonyl chloride using
method a. ms (esi(+))  xxxd2595xxx / xxxd3407xxx  ( xxxd2595xxx  + h)+; 1h nmr (300 mhz,
dmso-d6) delta 10.30 (s, 1h), 7.70 ( xxxd2595xxx , 1h), 7.25 ( xxxd2595xxx , 2h), 7.13 (d,
1h), 6.97 (d, 1h), 3.64 (s, 3 h), 2.70 ( xxxd2595xxx , 2 h), 2.50 ( xxxd2595xxx , 2h), 1.67
( xxxd2595xxx , 4 h).
methyl 2-{[(2,5-difluorophenyl)sulfonyl]amino}-5,6,7,8-tetrahydro-1-naphthalenecarboxylate (9c). the title compound was

figure 4.  xxxg1400xxx  inhibitors have similar ic50 values in inhibiting
proliferation and cellular  xxxg1400xxx  activity in ht-1080 cells. the cellular
 xxxg1400xxx  activity was assessed by the 35s  xxxd2595xxx  labeling of cells
in the presence of inhibitors, binding the proteins to a fast red column
and eluting the 35s  xxxd2595xxx  cleaved with exogenous  xxxg1400xxx . cell
proliferation was assessed using standard mts reagents.

prepared from 8 and 2,5-difluorophenylsulfonyl chloride using
method a. ms (esi(+))  xxxd2595xxx / xxxd3407xxx  ( xxxd2595xxx  + h)+; 1h nmr (300 mhz,
dmso-d6) delta 10.21 (s, 1h), 7.56 ( xxxd2595xxx , 2h), 7.41 ( xxxd2595xxx , 1h), 7.12 (d,
1h), 6.92 (d, 1h), 3.65 (s, 3 h), 2.69 ( xxxd2595xxx , 2 h), 2.50 ( xxxd2595xxx , 2h), 1.66
( xxxd2595xxx , 4 h).
methyl 2-{[(3-chloro-2-fluorophenyl)sulfonyl]amino}-5,6,7,8tetrahydro-1-naphthalenecarboxylate (9d). the title compound
was prepared from 8 and 3-chloro-2-fluorophenylsulfonyl chloride
using method a. ms [(-)-esi]  xxxd2595xxx /z 395.9 [ xxxd2595xxx  - h]-; 1h nmr
(300 mhz, dmso-d6) delta 10.28 (s, 1 h), 7.89 (ddd, j ) 8.2, 6.7,
1.7 hz, 1 h), 7.58 (ddd, j ) 7.9, 6.4, 1.7 hz, 1 h), 7.33 (dt, j )
8.1, 1.0 hz, 1 h), 7.12 (d, j ) 8.1 hz, 1 h), 6.96 (d, j ) 8.1 hz,
1 h), 3.65 (s, 3 h), 2.73-2.66 ( xxxd2595xxx , 2 h), 2.55-2.49 ( xxxd2595xxx , 2h), 1.701.61 ( xxxd2595xxx , 4 h); anal. (c18h17clfno4s) c, h, n.
methyl 2-{[(5-chloro-2-fluorophenyl)sulfonyl]amino}-5,6,7,8tetrahydro-1-naphthalenecarboxylate (9e). the title compound
was prepared from 8 and 5-chloro-2-fluorophenylsulfonyl chloride
using method a. ms (esi(+))  xxxd2595xxx /e 398 ( xxxd2595xxx  + h)+; 1h nmr (300
mhz, dmso-d6) delta 10.25 (s, 1h), 7.78 ( xxxd2595xxx , 1h), 7.58 (dd, 1h),
7.52 (t, 1h), 7.13 (d, 1h), 6.93 (d, 1h), 3.64 (s, 3 h), 2.70 ( xxxd2595xxx , 2
h), 2.53 ( xxxd2595xxx , 2h), 1.67 ( xxxd2595xxx , 4 h).
methyl 2-{[(4-chloro-2,5-difluorophenyl)sulfonyl]amino}5,6,7,8-tetrahydro-1-naphthalenecarboxylate (9f). the title compound was prepared from 8 and 4-chloro-2,5-difluorophenylsulfonyl
chloride using method a. ms (esi(+))  xxxd2595xxx /e 416 ( xxxd2595xxx  + h)+; 1h
nmr (300 mhz, dmso-d6) delta 10.35 (s, 1h), 7.97 (dd, 1h), 7.62
(dd, 1h), 7.12 (d, 1h), 6.94 (d, 1h), 3.66 (s, 3 h), 2.70 ( xxxd2595xxx , 2 h),
2.50 ( xxxd2595xxx , 2h), 1.67 ( xxxd2595xxx , 4 h).
methyl 2-{[(2-fluoro-5-methylphenyl)sulfonyl]amino}-5,6,7,8tetrahydro-1-naphthalenecarboxylate (9g). the title compound
was prepared from 8 and 2-fluoro-5-methylphenylsulfonyl chloride
using method a. ms (esi(+))  xxxd2595xxx /e 378 ( xxxd2595xxx  + h)+; 1h nmr (300
mhz, dmso-d6) delta 9.90 (s, 1h), 7.46 ( xxxd2595xxx , 2h), 7.31 (dd, 1h), 7.08
(d, 1h), 6.90 (d, 1h), 3.66 (s, 3 h), 2.68 ( xxxd2595xxx , 2 h), 2.50 ( xxxd2595xxx , 2h),
1.66 ( xxxd2595xxx , 4 h).
methyl 2-{[(4-chloro-2-fluorophenyl)sulfonyl]amino}-5,6,7,8tetrahydro-1-naphthalenecarboxylate (9h). the title compound
was prepared from 8 and 4-chloro-2-fluorophenylsulfonyl chloride
using method a. ms (esi(+))  xxxd2595xxx /e 398 ( xxxd2595xxx  + h)+; 1h nmr (300
mhz, dmso-d6) delta 10.15 (s, 1h), 7.73 (dd, 1h), 7.63 (t, 1h), 7.42
(dd, 1h), 7.11 (d, 1h), 6.93 (d, 1h), 3.65 (s, 3 h), 2.69 ( xxxd2595xxx , 2 h),
2.50 ( xxxd2595xxx , 2h), 1.66 ( xxxd2595xxx , 4 h).
methyl 2-{[(2-fluoro-4-methylphenyl)sulfonyl]amino}-5,6,7,8tetrahydro-1-naphthalenecarboxylate (9i). the title compound
was prepared from 8 and 2-fluoro-4-methylphenylsulfonyl chloride
using method a. ms (esi(+))  xxxd2595xxx /e 378 ( xxxd2595xxx  + h)+; 1h nmr (300
mhz, dmso-d6) delta 9.85 (s, 1h), 7.51 (t, 1h), 7.26 (d, 1h), 7.12
(d, 1h), 7.07 (d, 1h), 6.90 (d, 1h), 3.66 (s, 3 h), 2.67 ( xxxd2595xxx , 2 h),
2.50 ( xxxd2595xxx , 2h), 1.66 ( xxxd2595xxx , 4 h).

 xxxd189xxx  sulfonamide  xxxg1400xxx  inhibitors

methyl 2-{[(2-fluoro-5-(trifluoromethyl)phenyl)sulfonyl]amino}-5,6,7,8-tetrahydro-1-naphthalenecarboxylate (9j). the
title compound was prepared from 8 and 2-fluoro-5-(trifluoromethyl)phenylsulfonyl chloride using method a. ms (esi(+))  xxxd2595xxx /e
432 ( xxxd2595xxx  + h)+; 1h nmr (300 mhz, dmso-d6) delta 10.37 (s, 1h),
8.15 ( xxxd2595xxx , 1h), 7.87 (dd, 1h), 7.72 (t, 1h), 7.13 (d, 1h), 6.96 (d,
1h), 3.59 (s, 3 h), 2.70 ( xxxd2595xxx , 2 h), 2.51 ( xxxd2595xxx , 2h), 1.66 ( xxxd2595xxx , 4 h).
method b. 2-{[(2-{[3-(dimethylamino)propyl]amino}phenyl)sulfonyl]amino}-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid
(10e). a mixture of 9a (0.20 g, 0.57 mmol), triethylamine (0.21
ml, 1.5 mmol), acetonitrile (2.0 ml), and n,n-dimethyl-1,3propanediamine (0.35 ml, 3.2 mmol) was sealed in a 5 ml vessel
and heated in a microwave reactor for 1500 s at 200 °c. the
solution was cooled and adjusted to ph 4 with 1 n hcl. the
aqueous layer was extracted with ethyl acetate (3×), and the
combined organic fractions were washed with brine, dried ( xxxd2534xxx ),
filtered, and concentrated. the crude product was purified by
preparative rp hplc to provide the desired product as a tfa salt
(59%). ms (esi(+))  xxxd2595xxx /e 460 ( xxxd2595xxx  + h)+; (esi(-))  xxxd2595xxx /e 458 ( xxxd2595xxx  h)-. 1h nmr (300 mhz, dmso-d6) delta 13.15 (br s, 1h), 9.54 (s,
1h), 9.02 (br s, 1h), 7.51 (dd, 1h), 7.41 (dt, 1h), 6.96 (2, 1h),
6.86 (d, 1h), 6.64 ( xxxd2595xxx , 2h), 6.00 (t, 1h), 3.29 (q, 2h), 3.09 ( xxxd2595xxx ,
7h), 2.65 (br s, 4h), 1.89 ( xxxd2595xxx , 2h), 1.67 (br s, 4h), 1.14 (t, 6h).
anal. (c22h29n3o4s‚tfa) c, h, n.
2-{[(2-{[2-(dimethylamino)ethyl]amino}phenyl)sulfonyl]amino}-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid (10a).
the title compound was prepared from 9a and n,n-dimethylethylenediamine using method b. ms (dci)  xxxd2595xxx /e 418 ( xxxd2595xxx  + h)+; 1h
nmr (500 mhz, dmso-d6) delta 13.12 (br s, 1h), 9.52 (br s, 1h),
7.40 ( xxxd2595xxx , 2h), 6.95 (d, 1h), 6.90 (d, 1h), 6.88 (br s, 1h), 6.65 (t,
1h), 6.07 (t, 1h), 3.60 (q, 2h), 3.27 (t, 2h), 2.86 (s, 6h), 2.64 ( xxxd2595xxx ,
4h), 1.63 (br s, 4h). anal. (c21h27n3o4s‚tfa) c, h, n.
2-{[(2-{[2-(diethylamino)ethyl]amino}phenyl)sulfonyl]amino}5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid (10b). the title
compound was prepared from 9a and n,n-diethylethylenediamine
using method b. ms (dci)  xxxd2595xxx /e 446 ( xxxd2595xxx  + h)+; 1h nmr (500
mhz, dmso-d6) delta 13.18 (br s, 1h), 9.52 (br s, 1h), 7.42 ( xxxd2595xxx , 2h),
6.94 (d, 1h), 6.89 (d, 1h), 6.79 (br s, 1h), 6.67 ( xxxd2595xxx , 1h), 6.05 (br
s, 1h), 3.59 (q, 2h), 3.23 ( xxxd2595xxx , 6h), 2.64 ( xxxd2595xxx , 4h), 1.64 (br s, 4h),
1.20 (t, 6h). anal. (c23h31n3o4s‚2 tfa) c, h, n.
2-{[(2-{[2-(diisopropylamino)ethyl]amino}phenyl)sulfonyl]amino}-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid (10c).
the title compound was prepared from 9a and 2-(n,n-diisopropylamino)ethylamine using method b. ms (dci)  xxxd2595xxx /e 474 ( xxxd2595xxx  + h)+;
1h nmr (500 mhz, dmso-d ) delta 13.15 (br s, 1h), 9.45 (br s,
6
1h), 7.53 (d, 1h), 7.45 (t, 1h), 6.95 (d, 1h), 6.84 (d, 1h), 6.71
( xxxd2595xxx , 2h), 6.11 (br s, 1h), 1.80 ( xxxd2595xxx , 2h), 3.55 ( xxxd2595xxx , 2h), 3.25 ( xxxd2595xxx ,
2h), 2.65 ( xxxd2595xxx , 4h), 1.65 (br s, 4h), 1.28 (d, 12h). anal.
(c25h35n3o4s‚1.2 tfa) c, h, n.
2-{[(2-{[2-(1-pyrrolidinyl)ethyl]amino}phenyl)sulfonyl]amino}5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid (10d). the title
compound was prepared from 9a and 1-(2-aminoethyl)pyrrolidine
using method b. ms (dci)  xxxd2595xxx /e 444 ( xxxd2595xxx  + h)+; 1h nmr (500
mhz, dmso-d6) delta 9.85 (br s, 1h), 7.40 ( xxxd2595xxx , 2h), 6.96 (d, 1h),
6.89 ( xxxd2595xxx , 2h), 6.65 (t, 1h), 6.10 (t, 1h), 3.58 ( xxxd2595xxx , 4h), 3.30 ( xxxd2595xxx ,
4h), 2.64 (br s, 4h), 1.94 (br s, 4h), 1.63 (br s, 4h). anal.
(c23h29n3o4s‚1.1 tfa) c, h, n.
2-{[(2-{[3-(diethylamino)propyl]amino}phenyl)sulfonyl]amino}5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid (10f). the title
compound was prepared from 9a and n,n-diethyl-1,3-propanediamine using method b and converted to the hydrochloride salt by
treatment with hcl/dioxane. ms (esi(+))  xxxd2595xxx /e 460 ( xxxd2595xxx  + h)+;
(esi(-))  xxxd2595xxx /e 458 ( xxxd2595xxx  - h)-; 1h nmr (300 mhz, dmso-d6) delta
13.15 (br s, 1h), 9.54 (s, 1h), 9.02 (br s, 1h), 7.51 (dd, 1h), 7.41
(dt, 1h), 6.96 (2, 1h), 6.86 (d, 1h), 6.64 ( xxxd2595xxx , 2h), 6.00 (t, 1h),
3.29 (q, 2h), 3.09 ( xxxd2595xxx , 7h), 2.65 (br s, 4h), 1.89 ( xxxd2595xxx , 2h), 1.67 (br
s, 4h), 1.14 (t, 6h). anal. (c24h33n3o4s‚hcl‚h2o) c, h, n.
2-{[(2-{[3-(dibutylamino)propyl]amino}phenyl)sulfonyl]amino}-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid (10g).
the title compound was prepared from 9a and n,n-dibutyl-1,3propanediamine using method b. ms (dci)  xxxd2595xxx /e 516 ( xxxd2595xxx  + h)+;

journal of medicinal chemistry, 2006, vol. 49, no. 13 3839
1h

nmr (500 mhz, dmso-d6) delta 13.22 (br s, 1h), 9.59 (br s,
1h), 7.51 (d, 1h), 7.40 (t, 1h), 6.93 (d, 1h), 6.84 (d, 1h), 6.71 (br
s, 1h), 6.63 (t, 1h), 6.05 (br s, 1h), 3.16 (br s, 3h), 2.99 ( xxxd2595xxx , 5h),
2.68 (br s, 2h), 2.64 (br s, 2h), 1.88 ( xxxd2595xxx , 2h), 1.65 (br s, 4h), 1.52
( xxxd2595xxx , 4h), 1.28 ( xxxd2595xxx , 4h), 0.86 (t, 6h). anal. (c28h41n3o4s‚tfa) c,
h, n.
2-{[(2-{[3-(dimethylamino)-2,2-dimethylpropyl]amino}phenyl)sulfonyl]amino}-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid
(10h). the title compound was prepared from 9a and 3-n,n(dimethylamino)-2,2-dimethylpropylamine using method b. ms
(esi(+))  xxxd2595xxx /e 460 ( xxxd2595xxx  + h)+; (esi(-))  xxxd2595xxx /e 458 ( xxxd2595xxx  - h)-; 1h
nmr (300 mhz, dmso-d6) delta 7.53 (dd, 1h), 7.40 (dt, 1h), 6.97
(d, 1h), 6.92 (d, 1h), 6.68 (t, 1h), 6.58 (d, 1h), 3.09 (s, 2h), 3.06
( xxxd2595xxx , 2h), 2.83 (s, 6h), 2.66 ( xxxd2595xxx , 4h), 1.67 ( xxxd2595xxx , 4h), 1.01 (s, 6h).
anal. (c24h33n3o4s‚1.2 tfa) c, h, n.
2-({[2-({3-[bis(2-hydroxyethyl)amino]propyl}amino)phenyl]sulfonyl}amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid
(10i). the title compound was prepared from 9a and 2-[(3aminopropyl)(2-hydroxyethyl)amino]ethanol using method b. ms
(esi(+))  xxxd2595xxx /e 492 ( xxxd2595xxx  + h)+; (esi(-))  xxxd2595xxx /e 490 ( xxxd2595xxx  - h)-; 1h
nmr (300 mhz, dmso-d6) delta 7.50 (dd, 1h), 7.41 (dt, 1h), 6.96
(d, 1h), 6.85 (d, 1h), 6.64 ( xxxd2595xxx , 2h), 5.99 ( xxxd2595xxx , 1h), 3.73 (t, 4h),
3.24 ( xxxd2595xxx , 8h), 2.65 ( xxxd2595xxx , 4h), 1.96 ( xxxd2595xxx , 2h), 1.67 ( xxxd2595xxx , 4h). anal.
(c24h33n3o6s‚1.6 tfa) c, h, n.
2-{[(2-{[3-(ethylamino)propyl]amino}phenyl)sulfonyl]amino}5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid (10j). the title
compound was prepared from 9a and 3-ethylaminopropylamine
using method b. ms (esi(+))  xxxd2595xxx /e 432 ( xxxd2595xxx  + h)+; (esi(-))  xxxd2595xxx /e
430 ( xxxd2595xxx  - h)-; 1h nmr (300 mhz, dmso-d6) delta 7.51 (dd, 1h),
7.40 (dt, 1h), 6.94 (d, 1h), 6.84 (d, 1h), 6.63 ( xxxd2595xxx , 2h), 6.01 ( xxxd2595xxx ,
1h), 3.31 ( xxxd2595xxx , 2h), 2.95 ( xxxd2595xxx , 4h), 2.65 ( xxxd2595xxx , 4h), 1.85 ( xxxd2595xxx , 2h), 1.66
( xxxd2595xxx , 4h), 1.15 (t, 3h). anal. (c22h29n3o4s‚1.25 tfa) c, h, n.
2-({[2-({3-[(2-hydroxyethyl)amino]propyl}amino)phenyl]sulfonyl}amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid
(10k). the title compound was prepared from 9a and 2-[(3aminopropyl)amino]ethanol using method b. ms (esi(+))  xxxd2595xxx /e 448
( xxxd2595xxx  + h)+; (esi(-))  xxxd2595xxx /e 446 ( xxxd2595xxx  - h)-; 1h nmr (300 mhz,
dmso-d6) delta 7.51 (dd, 1h), 7.41 (dt, 1h), 6.95 (d, 1h), 6.84 (d,
1h), 6.64 ( xxxd2595xxx , 2h), 6.00 ( xxxd2595xxx , 1h), 3.63 (t, 2h), 3.28 ( xxxd2595xxx , 2h), 2.96
( xxxd2595xxx , 4h), 2.65 ( xxxd2595xxx , 4h), 1.89 ( xxxd2595xxx , 2h), 1.67 ( xxxd2595xxx , 4h). anal.
(c22h29n3o5s‚1.4 tfa) c, h, n.
2-({[2-({3-[(tert-butoxycarbonyl)amino]propyl}amino)phenyl]sulfonyl}amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid
(10l). the title compound was prepared from 9a and tert-butyl
3-aminopropylcarbamate using method b and purified by rp hplc
with an ammonium acetate buffer. ms (esi(+))  xxxd2595xxx /e 504 ( xxxd2595xxx  +
h)+, 526 ( xxxd2595xxx  + na)+; (esi(-))  xxxd2595xxx /e 502 ( xxxd2595xxx  - h)-; 1h nmr (300
mhz, dmso-d6) delta 7.47 (dd, 1h), 7.37 (dt, 1h), 6.95 (d, 1h), 6.76
(d, 1h), 6.60 ( xxxd2595xxx , 2h), 5.90 ( xxxd2595xxx , 1h), 3.14 ( xxxd2595xxx , 2h), 2.97 (q, 2h),
2.65 ( xxxd2595xxx , 4h), 1.66 ( xxxd2595xxx , 4h), 1.64 ( xxxd2595xxx , 2h), 1.38 (s, 9h). anal.
(c25h33n3o6s) c, h, n.
2-({[2-({3-[(tert-butoxycarbonyl)(methyl)amino]propyl}amino)phenyl]sulfonyl}-amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid (10m). the title compound was prepared from 9a
and tert-butyl 3-aminopropyl(methyl)carbamate using method b and
purified by rp hplc with an ammonium acetate buffer. ms
(esi(+))  xxxd2595xxx /e 518 ( xxxd2595xxx  + h)+, 540 ( xxxd2595xxx  + na)+; (esi(-))  xxxd2595xxx /e 516
( xxxd2595xxx  - h)-; 1h nmr (300 mhz, dmso-d6) delta 7.49 (dd, 1h), 7.38
(dt, 1h), 6.94 (d, 1h), 6.75 (d, 1h), 6.60 ( xxxd2595xxx , 2h), 5.89 ( xxxd2595xxx , 1h),
3.19 ( xxxd2595xxx , 2h), 3.10 ( xxxd2595xxx , 2h), 2.76 (s, 3h), 2.65 ( xxxd2595xxx , 4h), 1.71 ( xxxd2595xxx ,
2h), 1.66 ( xxxd2595xxx , 4h), 1.36 (s, 9h). anal. (c26h35n3o6s) c, h, n.
2-[({2-[(3-aminopropyl)amino]phenyl}sulfonyl)amino]-5,6,7,8tetrahydro-1-naphthalenecarboxylic acid (10n). compound 10q
(0.035 g, 0.070 mmol) was dissolved in saturated hcl/dioxane (2
ml), stirred for 1 h, concentrated, treated with  xxxd2052xxx , and
then concentrated to provide the desired product. ms (esi(+))  xxxd2595xxx /e
404 ( xxxd2595xxx  + h)+, 426 ( xxxd2595xxx  + na)+; (esi(-))  xxxd2595xxx /e 402 ( xxxd2595xxx  - h)-; 1h
nmr (300 mhz, dmso-d6) delta 7.48 (dd, 1h), 7.41 (dt, 1h), 6.95
(d, 1h), 6.84 (d, 1h), 6.60 ( xxxd2595xxx , 2h), 5.98 ( xxxd2595xxx , 1h), 3.28 ( xxxd2595xxx , 2h),
2.85 ( xxxd2595xxx , 2h), 2.65 ( xxxd2595xxx , 4h), 1.84 ( xxxd2595xxx , 2h), 1.67 ( xxxd2595xxx , 4h). anal.
(c20h25n3o4s‚hcl‚h2o) c, h, n.

3840

journal of medicinal chemistry, 2006, vol. 49, no. 13

2-{[(2-{[3-(4-methyl-1-piperazinyl)propyl]amino}phenyl)sulfonyl]amino}-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid
(10o). the title compound was prepared from 9a and 3-(4-methyl1-piperazinyl)-1-propanamine using method b. ms (dci)  xxxd2595xxx /e 487
( xxxd2595xxx  + h)+; 1h nmr (500 mhz, dmso-d6) delta 9.56 (br s, 1h), 7.50
(dd, 1h), 7.39 ( xxxd2595xxx , 1h), 6.96 (d, 1h), 6.80 (d, 1h), 6.66 (d, 1h),
6.62 (t, 1h), 6.02 (br s, 1h), 3.30 (t, 4h), 3.20 ( xxxd2595xxx , 4h), 2.73 (br
s, 3h), 2.65 ( xxxd2595xxx , 4h), 1.66 ( xxxd2595xxx , 4h). anal. (c25h34n4o4s‚3 tfa‚
h2o) c, h, n.
2-{[(2-{[3-(1-piperidinyl)propyl]amino}phenyl)sulfonyl]amino}5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid (10p). the title
compound was prepared from 9a and 1-(3-aminopropyl)piperidine
using method b. ms (dci)  xxxd2595xxx /e 472 ( xxxd2595xxx  + h)+; 1h nmr (500
mhz, dmso-d6) delta 13.22 (br s, 1h), 9.54 (br s, 1h), 7.51 (d, 1h),
7.40 (t, 1h), 6.94 (d, 1h), 6.82 (d, 1h), 6.63 ( xxxd2595xxx , 1h), 6.05 (br s,
1h), 3.27 ( xxxd2595xxx , 4h), 3.10 ( xxxd2595xxx , 2h), 2.67-2.64 ( xxxd2595xxx , 4h), 1.89 ( xxxd2595xxx ,
2h), 1.78 (br s, 2h), 1.58 (br s, 2h), 1.65 (br s, 6h). anal.
(c25h33n3o4s‚tfa) c, h, n.
2-{[(2-{[3-(4-morpholinyl)propyl]amino}phenyl)sulfonyl]amino}-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid (10q).
the title compound was prepared from 9a and 1-(3-aminopropyl)morpholine using method b. ms (dci)  xxxd2595xxx /e 474 ( xxxd2595xxx  + h)+; 1h
nmr (500 mhz, dmso-d6) delta 7.44 (d, 1h), 7.33 (t, 1h), 7.08 (br
s, 1h), 6.92 (d, 1h), 6.76 (d, 1h), 6.54 (t, 1h), 6.18 (br s, 1h),
3.79 (br s, 4h), 3.26-3.17 ( xxxd2595xxx , 8h), 2.73 (br s, 2h), 2.62 (br s,
2h), 1.81 (br s, 2h), 1.62 (br s, 4h). anal. (c24h31n3o5s‚0.67
tfa) c, h, n.
2-{[(2-{[3-(1-pyrrolidinyl)propyl]amino}phenyl)sulfonyl]amino}-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid (10r).
the title compound was prepared from 9a and 1-(3-aminopropyl)pyrrolidine using method b. ms (dci)  xxxd2595xxx /e 458 ( xxxd2595xxx  + h)+; 1h
nmr (500 mhz, dmso-d6) delta 13.14 (br s, 1h), 9.72 (br s, 1h),
7.51 (dd, 1h), 7.40 ( xxxd2595xxx , 1h), 6.95 (d, 1h), 6.83 (d, 1h), 6.72 (br s,
1h), 6.64 (t, 1h), 6.01 (br s, 1h), 3.27 ( xxxd2595xxx , 4h), 3.18 ( xxxd2595xxx , 4h),
2.67-2.64 ( xxxd2595xxx , 4h), 1.89 ( xxxd2595xxx , 6h), 1.65 (br s, 4h). anal.
(c24h31n3o4s‚tfa) c, h, n.
2-({[2-({2-[1-methyl-2-pyrrolidinyl]ethyl}amino)phenyl]sulfonyl}amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid
(10s). the title compound was prepared from 9a and 2-(2aminoethyl)-1-methylpyrrolidine using method b. ms (esi(+))  xxxd2595xxx /e
458 ( xxxd2595xxx  + h)+, 480 ( xxxd2595xxx  + na)+; (esi(-))  xxxd2595xxx /e 456 ( xxxd2595xxx  - h)-; 1h
nmr (300 mhz, dmso-d6) delta 13.20 (br s, 1h), 10.02 (br s, 1h),
9.54 (s, 1h), 7.52 (dd, 1h), 7.42 (dt, 1h), 6.96 (d, 1h), 6.86 (d,
1h), 6.65 (t, 1h), 6.60 (d, 1h), 5.97 (br s, 1h), 3.26 ( xxxd2595xxx , 4h), 2.98
(quint, 1h), 2.72 (d, 3h), 2.65 (br s, 4h), 2.33-2.13 ( xxxd2595xxx , 2h), 2.001.75 ( xxxd2595xxx , 2h), 1.67 (br s, 5h). anal. (c24h31n3o4s‚1.33 tfa) c,
h, n.
2-[({2-[(1-benzyl-4-piperidinyl)amino]phenyl}sulfonyl)amino]5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid (10t). the title
compound was prepared from 9a and 4-amino-1-benzylpiperidine
using method b. ms (esi(+))  xxxd2595xxx /e 520 ( xxxd2595xxx  + h)+; ms (esi(-))
 xxxd2595xxx /e 518 ( xxxd2595xxx  - h)-; 1h nmr (300 mhz, dmso-d6) delta 9.63 (s,
1h), 7.51 ( xxxd2595xxx , 6h), 7.37 ( xxxd2595xxx , 1h), 6.93 (d, 1h), 6.89 (d, 1h), 6.65
( xxxd2595xxx , 1h), 6.55 (d, 1h), 5.72 (d, 1h), 4.33 ( xxxd2595xxx , 1h), 3.96 (s, 2h),
3.44 ( xxxd2595xxx , 2h), 3.06 ( xxxd2595xxx , 2h), 2.65 ( xxxd2595xxx , 4h), 211 ( xxxd2595xxx , 2h), 1.96 ( xxxd2595xxx ,
2h), 1.65 ( xxxd2595xxx , 4h). anal. (c29h33n3o4s‚1 tfa) c, h, n.
2-[({2-[(1,2,2,6,6-pentamethyl-4-piperidinyl)amino]phenyl}sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid
(10u). the title compound was prepared from 9a and 4-amino1,2,2,6,6-pentamethylpiperidine using method b. ms (esi(+))  xxxd2595xxx /e
500 ( xxxd2595xxx  + h)+; ms (esi(-))  xxxd2595xxx /e 498 ( xxxd2595xxx  - h)-; 1h nmr (300
mhz, dmso-d6) delta 9.68 (s, 1h), 8.45 (s, 1h), 7.52 (dd, 1h), 7.42
(ddd, 1h), 6.94 (d, 1h), 6.68 (t, 1h), 6.50 (d, 1h), 5.70 (d, 1h),
3.99 ( xxxd2595xxx , 1h), 2.75 (s, 3h), 2.67 ( xxxd2595xxx , 4h), 2.10 ( xxxd2595xxx , 2h), 1.68 ( xxxd2595xxx ,
4h), 1.57 (t, 2h), 1.46 (s, 6h), 1.40 (s, 6h). anal. (c27h37n3o4s‚
1.25 tfa) c, h, n.
2-{[(2-{[3-piperidinylmethyl]amino}phenyl)sulfonyl]amino}5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid (10v). the title
compound was prepared from 9a and 1-tert-butoxycarbonyl-3(aminomethyl)piperidine using method b and deprotected with
saturated hcl/dioxane. ms (esi(+))  xxxd2595xxx /e 444 ( xxxd2595xxx  + h)+, 461

sheppard et al.

( xxxd2595xxx +nh4)+, 466 ( xxxd2595xxx  + na)+; (esi(-))  xxxd2595xxx /e 442 ( xxxd2595xxx  - h)-; 1h
nmr (300 mhz, dmso-d6) delta 7.51 (dd, 1h), 7.38 (dt, 1h), 6.96
(d, 1h), 6.82 (d, 1h), 6.63 ( xxxd2595xxx , 2h), 6.04 ( xxxd2595xxx , 1h), 3.69 ( xxxd2595xxx , 1h),
3.49 ( xxxd2595xxx , 1h), 3.08 ( xxxd2595xxx , 2h), 2.83 ( xxxd2595xxx , 2h), 2.65 ( xxxd2595xxx , 4h), 1.83 ( xxxd2595xxx ,
3h), 1.67 ( xxxd2595xxx , 4h), 1.29 ( xxxd2595xxx , 2h). anal. (c23h29n3o4s‚1 tfa) c,
h, n.
2-{[(2-{[3-pyrrolidinylmethyl]amino}phenyl)sulfonyl]amino}5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid (10w). the title
compound was prepared from 9a and 1-tert-butoxycarbonyl-3(aminomethyl)pyrrolidine using method b and deprotected with
saturated hcl/dioxane. ms (esi(+))  xxxd2595xxx /e 430 ( xxxd2595xxx  + h)+;
(esi(-))  xxxd2595xxx /e 428 ( xxxd2595xxx  - h)-; 1h nmr (300 mhz, dmso-d6)
delta 7.51 (dd, 1h), 7.40 (dt, 1h), 6.95 (d, 1h), 6.87 (d, 1h), 6.65
(t, 1h), 6.59 (d, 1h), 6.01 ( xxxd2595xxx , 1h), 3.11 ( xxxd2595xxx , 4h), 3.02 ( xxxd2595xxx , 2h),
2.65 ( xxxd2595xxx , 4h), 2.02 ( xxxd2595xxx , 1h), 1.67 ( xxxd2595xxx , 4h) 1.28 ( xxxd2595xxx , 2h). anal.
(c22h27n3o4s‚1.33 tfa) c, h, n.
2-[({2-[(4-piperidinylmethyl)amino]phenyl}sulfonyl)amino]5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid (10x). the title
compound was prepared from 9a and 1-tert-butoxycarbonyl-4(aminomethyl)piperidine using method b and deprotected with
saturated hcl/dioxane. ms (esi(+))  xxxd2595xxx /e 444 ( xxxd2595xxx  + h)+, 466 ( xxxd2595xxx 
+ na)+; (esi(-))  xxxd2595xxx /e 442 ( xxxd2595xxx  - h)-; 1h nmr (300 mhz, dmsod6) delta 7.51 (dd, 1h), 7.38 (dt, 1h), 6.95 (d, 1h), 6.82 (d, 1h), 6.63
( xxxd2595xxx , 2h), 3.26 (d, 2h), 3.06 ( xxxd2595xxx , 2h), 2.81, ( xxxd2595xxx , 2h), 2.66 ( xxxd2595xxx , 4h),
1.83 ( xxxd2595xxx , 3h), 1.67 ( xxxd2595xxx , 4h), 1.33 ( xxxd2595xxx , 2h). anal. (c23h29n3o4s‚1
tfa) c, h, n.
2-({[2-({2-[(2s)-2-pyrrolidinyl]ethyl}amino)phenyl]sulfonyl}amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid (10y).
compound 12 (0.13 g, 0.3 mmol), lithium hydroxide (0,127 g, 3.0
mmol), dioxane (3 ml), and water (1.5 ml) were sealed in a vial
and microwaved at 160 °c for 15 min. the reaction mixture was
concentrated and the residues purified by c18 reverse-phase hplc
using acetonitrile/water/0.1% tfa to provide the desired product.
ms (dci)  xxxd2595xxx /e 444 ( xxxd2595xxx  + h)+; 1h nmr (500 mhz, cd3od) 7.54
(dd, 1h), 7.38 ( xxxd2595xxx , 1h), 7.13 (d, 1h), 7.02 (d, 1h), 6.80 (d, 1h),
6.65 ( xxxd2595xxx , 1h), 3.71 ( xxxd2595xxx , 1h), 3.44 (t, 1h), 2.72 (br  xxxd2595xxx , 4h), 2.382.27 ( xxxd2595xxx , 2h), 2.14-2.00 ( xxxd2595xxx , 4h), 1.72 ( xxxd2595xxx , 4h). anal. (c23h29n3o4s‚
1.25 tfa) c, h, n.
2-[2-(3-(4-(1-piperidinyl)1-piperidinyl)propylamino)-benzenesulfonylamino]-5,6,7,8-tetrahydronaphthalene-1-carboxylic acid
(10z). the title compound was prepared from 9a and n-(3diethylaminopropyl)- xxxd13xxx  using method b.
ms (esi(+))  xxxd2595xxx /e 555 ( xxxd2595xxx  + h)+; 1h nmr (400 mhz, meoh-d4)
delta 7.50 (dd, j ) 7.96, 1.65 hz, 1 h); 7.35 (ddd, j ) 8.54, 7.10,
1.65 hz, 1 h); 7.17 (d, j ) 8.23 hz, 1 h); 7.02 (d, j ) 8.37 hz,
1 h); 6.80 (d, j ) 7.68 hz, 1 h); 6.61 (td, j ) 7.62, 0.96 hz,
1 h); 3.81 (d, j ) 12.76 hz, 2 h); 3.45-3.60 ( xxxd2595xxx , j ) 11.97, 11.97,
3.57, 3.36 hz, 3 h); 3.31-3.36 ( xxxd2595xxx , 4 h); 3.03-3.14 ( xxxd2595xxx , 3 h);
2.67-2.78 ( xxxd2595xxx , 4 h); 2.37 (d, j ) 13.86 hz, 2 h); 2.02-2.17 ( xxxd2595xxx ,
4 h); 1.91-2.01 ( xxxd2595xxx , 2 h); 1.76-1.89 ( xxxd2595xxx , 3 h); 1.66-1.76 ( xxxd2595xxx , 5
h). anal. (c30h42n4o4s‚3 tfa‚h2o) c, h, n.
2-{[(2-{[3-(1h-imidazol-1-yl)propyl]amino}phenyl)sulfonyl]amino}-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid (10aa).
the title compound was prepared from 9a and 1-(3-aminopropyl)imidazole using method b. ms (dci)  xxxd2595xxx /e 455 ( xxxd2595xxx  + h)+; 1h nmr
(500 mhz, dmso-d6) delta 13.87 (br s, 1h), 9.56 (br s, 1h), 9.03 (br
s, 1h), 7.74 (s, 1h), 7.67 (s, 1h), 7.51 (dd, 1h), 7.39 ( xxxd2595xxx , 1h),
6.95 (d, 1h), 6.78 (d, 1h), 6.67-6.63 ( xxxd2595xxx , 2h), 5.93 (t, 1h), 3.203.16 ( xxxd2595xxx , 4h), 2.63 ( xxxd2595xxx , 4h), 2.10 ( xxxd2595xxx , 2h), 1.65 (br s, 4h). anal.
(c23h26n4o4s‚1.25 tfa) c, h, n.
2-[({2-[(4-pyridinylmethyl)amino]phenyl}sulfonyl)amino]5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid (10ab). the title
compound was prepared from 9a and 4-aminomethylpyridine using
method b. ms (esi(+))  xxxd2595xxx /e 438 ( xxxd2595xxx  + h)+; (esi(-))  xxxd2595xxx /e 436 ( xxxd2595xxx 
- h)-; 1h nmr (300 mhz, dmso-d6) delta 8.64 (d, 2h), 7.62 (d,
2h), 7.56 (dd, 1h), 7.30 (dt, 1h), 6.97 (d, 1h), 6.65 ( xxxd2595xxx , 2h), 6.57
(d, 1h), 4.66 (d, 2h), 2.67 ( xxxd2595xxx , 4h), 1.68 ( xxxd2595xxx , 4h). anal.
(c23h23n3o4s‚1 tfa) c, h, n.
2-{[(2-{[2-(2-pyridinyl)ethyl]amino}phenyl)sulfonyl]amino}5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid (10ac). the title
compound was prepared from 9a and 2-(2-aminoethyl)pyridine

 xxxd189xxx  sulfonamide  xxxg1400xxx  inhibitors

using method b. ms (dci)  xxxd2595xxx /e 452 ( xxxd2595xxx  + h)+; 1h nmr (400
mhz, dmso-d6) delta 8.51 (ddd, 1h), 7.70 (td, 1h), 7.54 (dd, 1h),
7.33 (d, 1h), 7.29 (ddd, 1h), 7.22 (ddd, 1h), 6.90 (d, 1h), 6.80 (d,
1h), 6.76 (d, 1h), 6.58 ( xxxd2595xxx , 1h), 6.14 (br s, 1h), 3.47 (t, 2h), 3.02
(t, 2h), 2.90 ( xxxd2595xxx , 2h), 2.59 ( xxxd2595xxx , 2h), 1.60 ( xxxd2595xxx , 4h). anal.
(c24h25n3o4s‚1 tfa) c, h, n.
2-{[(2-{[2-(4-pyridinyl)ethyl]amino}phenyl)sulfonyl]amino}5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid (10ad). the title
compound was prepared from 9a and 4-(2-aminoethyl)pyridine
using method b. ms (esi(+))  xxxd2595xxx /e 452 ( xxxd2595xxx  + h)+; ms (esi(-))
 xxxd2595xxx /e 450 ( xxxd2595xxx  - h)-; 1h nmr (300 mhz, dmso-d6) delta 9.48 (s,
1h), 8.63 (d, 2h), 7.66 (d, 2h), 7.49 (dd, 1h), 7.40 (t, 1h), 6.95
(d, 1h), 6.89 (d, 1h), 6.65 (d, 1h), 6.59 (d, 1h), 5.97 (bd s, 1h),
3.01 (t, 2h), 2.66 ( xxxd2595xxx , 4h), 2.55 ( xxxd2595xxx , 2h), 1.66 ( xxxd2595xxx , 4h). anal.
(c24h25n3o4s‚1 tfa) c, h, n.
2-{[(2-{[3-(2-oxo-1-pyrrolidinyl)propyl]amino}phenyl)sulfonyl]amino}-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid (10ae).
the title compound was prepared from 9a and 1-(3-aminopropyl)2-pyrrolidinone using method b. ms (dci)  xxxd2595xxx /e 472 ( xxxd2595xxx  + h)+;
1h nmr (500 mhz, dmso-d ) delta 13.11 (br s, 1h), 9.50 (br s,
6
1h), 7.48 (dd, 1h), 7.37 ( xxxd2595xxx , 1h), 6.94 (d, 1h), 6.76 (d, 1h), 6.60
( xxxd2595xxx , 2h), 5.91 ( xxxd2595xxx , 1h), 3.32 (t, 2h), 3.22 (t, 2h), 3.11 ( xxxd2595xxx , 2h),
2.65 ( xxxd2595xxx , 4h), 2.23 (t, 2h), 1.92 ( xxxd2595xxx , 2h), 1.71 ( xxxd2595xxx , 2h), 1.66 (br s,
4h). anal. (c24h29n3o5s‚0.67 h2o) c, h, n.
2-[2-(3-diethylaminopropylamino)-6-fluorobenzenesulfonylamino]-5,6,7,8-tetrahydronaphthalene-1-carboxylic acid (10af).
the title compound was prepared from 9b and n,n-diethyl-1,3propanediamine using method b. ms [esi]  xxxd2595xxx /z 478 [ xxxd2595xxx  + h]+;
1h nmr (300 mhz, dmso-d ) delta 7.26-7.21 ( xxxd2595xxx , 2h), 6.87 (d,
6
1h), 6.52 (d, 1h), 6.28 (dd, 1h), 3.30 ( xxxd2595xxx , 4h), 3.10 ( xxxd2595xxx , 4h), 2.83
( xxxd2595xxx , 2h), 2.60 ( xxxd2595xxx , 2h), 1.79 ( xxxd2595xxx , 2h), 1.59 ( xxxd2595xxx , 4h), 1.17 (t, 6h).
anal. (c24h32fn3o4s‚0.75 h2o) c, h, n.
2-[2-(3-diethylaminopropylamino)-5-fluorobenzenesulfonylamino]-5,6,7,8-tetrahydronaphthalene-1-carboxylic acid (10ag).
the title compound was prepared from 9c and n,n-diethyl-1,3propanediamine using method b. ms [esi]  xxxd2595xxx /z 478 [ xxxd2595xxx  + h]+;
1h nmr (300 mhz, dmso-d ) delta 7.50 ( xxxd2595xxx , 1h), 7.40-7.30 ( xxxd2595xxx ,
6
2h), 7.08 (d, 1h), 6.86 (d, 1h), 3.50 (q, 4h), 3.42 ( xxxd2595xxx , 2h), 3.07
( xxxd2595xxx , 2h), 2.98 ( xxxd2595xxx , 4h), 2.59 ( xxxd2595xxx , 2h), 1.59 ( xxxd2595xxx , 4h), 1.16 (t, 6h).
anal. (c24h32fn3o4s‚tfa) c, h, n.
2-[3-chloro-2-(3-diethylaminopropylamino)-benzenesulfonylamino]-5,6,7,8-tetrahydronaphthalene-1-carboxylic acid (10ah).
the title compound was prepared from 9d and n,n-diethyl-1,3propanediamine using method b. ms [(-)-esi]  xxxd2595xxx /z 492.1 [ xxxd2595xxx  h]-; 1h nmr (300 mhz, dmso-d6) delta 7.74 (dd, j ) 7.8, 1.4 hz,
1 h), 7.51 (dd, j ) 8.0, 1.2 hz, 1 h), 7.15 (d, j ) 8.5 hz, 1 h),
6.94 (t, j ) 8.0 hz, 1 h), 6.87 (d, j ) 8.5 hz, 1 h), 3.42-3.24
( xxxd2595xxx , 4 h), 3.18-3.06 ( xxxd2595xxx , 6 h), 2.93-2.85 ( xxxd2595xxx , 2 h), 2.63-2.54
( xxxd2595xxx , 2 h), 2.07-1.94 ( xxxd2595xxx , 2 h), 1.63-1.55 ( xxxd2595xxx , 4 h), 1.21 (t, j )
7.1 hz, 6 h). anal. (c24h32cln3o4s‚0.67 h2o) c, h, n.
2-[5-chloro-2-(3-diethylaminopropylamino)-benzenesulfonylamino]-5,6,7,8-tetrahydronaphthalene-1-carboxylic acid (10ai).
the title compound was prepared from 9e and n,n-diethyl-1,3propanediamine using method b. ms [esi]  xxxd2595xxx /z 494 [ xxxd2595xxx  + h]+;
1h nmr (300 mhz, dmso-d ) delta 7.35 (d, 1h), 7.32 (dd, 1h),
6
7.26 (d, 1h), 6.93 (d, 1h), 6.76 (d, 1h), 3.26 ( xxxd2595xxx , 4h), 3.07 ( xxxd2595xxx ,
4h), 2.79 ( xxxd2595xxx , 2h), 2.61 ( xxxd2595xxx , 2h), 1.75 ( xxxd2595xxx , 2h), 1.59 ( xxxd2595xxx , 4h), 1.17
(t, 6h). anal. (c24h32cln3o4s‚2 h2o) c, h, n.
2-[4-chloro-2-(3-diethylaminopropylamino)-5-fluorobenzenesulfonylamino]-5,6,7,8-tetrahydronaphthalene-1-carboxylic acid
(10aj). the title compound was prepared from 9f and n,n-diethyl1,3-propanediamine using method b. ms [esi]  xxxd2595xxx /z 512 [ xxxd2595xxx  + h]+;
1h nmr (300 mhz, dmso-d ) delta 7.36 (d, 1h), 7.26 (d, 1h), 6.92
6
(d, 1h), 6.88 (d, 1h), 3.22 ( xxxd2595xxx , 4h), 3.09 ( xxxd2595xxx , 4h), 2.82 ( xxxd2595xxx , 2h),
2.61 ( xxxd2595xxx , 2h), 1.75 ( xxxd2595xxx , 2h), 1.59 ( xxxd2595xxx , 4h), 1.17 (t, 6h). anal.
(c24h31clfn3o4s‚0.5 h2o) c, h, n.
2-[2-(3-diethylaminopropylamino)-5-methylbenzenesulfonylamino]-5,6,7,8-tetrahydronaphthalene-1-carboxylic acid (10ak).
the title compound was prepared from 9g and n,n-diethyl-1,3propanediamine using method b. ms [esi]  xxxd2595xxx /z 474 [ xxxd2595xxx  + h]+;
1h nmr (300 mhz, dmso-d ) delta 7.36 ( xxxd2595xxx , 1h), 7.25 (d, 1h), 6.96
6

journal of medicinal chemistry, 2006, vol. 49, no. 13 3841

(d, 1h), 6.78 (d, 1h), 6.67 ( xxxd2595xxx , 1h), 3.24 ( xxxd2595xxx , 4h), 3.09 ( xxxd2595xxx , 4h),
2.66 ( xxxd2595xxx , 4h), 1.85 ( xxxd2595xxx , 2h), 1.67 ( xxxd2595xxx , 4h), 1.13 (t, 6h). anal.
(c25h35n3o4s‚tfa) c, h, n.
2-[4-chloro-2-(3-diethylaminopropylamino)benzenesulfonylamino]-5,6,7,8-tetrahydronaphthalene-1-carboxylic acid (10al).
the title compound was prepared from 9h and n,n-diethyl-1,3propanediamine using method b. ms [esi]  xxxd2595xxx /z 494 [ xxxd2595xxx  + h]+;
1h nmr (300 mhz, dmso-d ) delta 7.47 (d, 1h), 6.97 (d, 1h), 6.87
6
(s, 1h), 6.65 ( xxxd2595xxx , 1h), 3.34 ( xxxd2595xxx , 4h), 3.11 ( xxxd2595xxx , 4h), 2.66 ( xxxd2595xxx , 4h),
1.84 ( xxxd2595xxx , 2h), 1.66 ( xxxd2595xxx , 4h), 1.15 (t, 6h). anal. (c24h32cln3o4s‚
tfa) c, h, n.
2-[2-(3-diethylaminopropylamino)-4-methylbenzenesulfonylamino]-5,6,7,8-tetrahydronaphthalene-1-carboxylic acid (10am).
the title compound was prepared from 9i and n,n-diethyl-1,3propanediamine using method b. ms [esi]  xxxd2595xxx /z 474 [ xxxd2595xxx  + h]+;
1h nmr (300 mhz, dmso-d ) delta 7.41 (d, 1h), 6.96 (d, 1h), 6.65
6
(s, 1h), 6.65 ( xxxd2595xxx , 1h), 6.47 (d, 1h), 3.27 ( xxxd2595xxx , 4h), 3.10 ( xxxd2595xxx , 4h),
2.65 ( xxxd2595xxx , 4h), 1.87 ( xxxd2595xxx , 2h), 1.66 ( xxxd2595xxx , 4h), 1.14 (t, 6h). anal.
(c25h35n3o4s‚1.4 tfa) c, h, n.
2-[2-(3-diethylaminopropylamino)-5-(trifluoromethyl)benzenesulfonylamino]-5,6,7,8-tetrahydronaphthalene-1-carboxylic acid
(10an). the title compound was prepared from 9j and n,n-diethyl1,3-propanediamine using method b. ms [esi]  xxxd2595xxx /z 528[ xxxd2595xxx  + h]+;
1h nmr (300 mhz, dmso-d ) delta 7.71 ( xxxd2595xxx , 2h), 7.02 (d, 1h), 6.98
6
(d, 1h), 6.53 ( xxxd2595xxx , 1h), 3.37 ( xxxd2595xxx , 4h), 3.11 ( xxxd2595xxx , 4h), 2.66 ( xxxd2595xxx , 4h),
1.88 ( xxxd2595xxx , 2h), 1.67 ( xxxd2595xxx , 4h), 1.15 (t, 6h). anal. (c25h32f3n3o4s‚
1.1 tfa) c, h, n.
2-{[(2-{[4-(n,n-dimethylamino)butyl]amino}phenyl)sulfonyl]amino}-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid (10ao).
the title compound was prepared from 9a and 4-(n,n-dimethylamino)butylamine using method b. ms (dci)  xxxd2595xxx /e 446 ( xxxd2595xxx  + h)+;
1h nmr (500 mhz, dmso-d ) delta 13.09 (br s, 1h), 9.52 (br s,
6
1h), 7.51 (d, 1h), 7.38 ( xxxd2595xxx , 1h), 6.95 (d, 1h), 6.79 (d, 1h), 6.68
(br s, 1h), 6.62 (t, 1h), 5.90 (br s, 1h), 3.18 ( xxxd2595xxx , 2h), 3.06 ( xxxd2595xxx ,
2h), 2.74 (s, 6h), 2.68-2.65 ( xxxd2595xxx , 4h), 1.69-1.66 ( xxxd2595xxx , 6h), 1.57
( xxxd2595xxx , 2h). anal. (c23h31n3o4s‚1.9 tfa) c, h, n.
2-{[(2-{[4-(diethylamino)-1-methylbutyl]amino}phenyl)sulfonyl]amino}-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid
(10ap). the title compound was prepared from 9d and 4-(n,ndiethylamino)-1-methylbutylamine using method b. ms (dci)  xxxd2595xxx /e
488 ( xxxd2595xxx  + h)+; 1h nmr (500 mhz, dmso-d6) delta 13.10 (br s,
1h), 9.66 (br s, 1h), 7.54 (d, 1h), 7.35 (t, 1h), 6.93 (d, 1h), 6.80
(d, 1h), 6.59 (t, 1h), 5.65 (d, 1h), 3.63 ( xxxd2595xxx , 1h), 3.07-2.97 (br  xxxd2595xxx ,
6h), 2.63 (br s, 4h), 1.76-1.47 (br  xxxd2595xxx , 8h), 1.16 (t, 6h), 1.10 (d,
3h). anal. (c26h37n3o4s‚tfa) c, h, n.
2-{[(2-aminophenyl)sulfonyl]amino}-5,6,7,8-tetrahydro-1naphthalenecarboxylic acid (11a). methyl 2-{[(2-nitrophenyl)sulfonyl]amino}-5,6,7,8-tetrahydro-1-naphthalenecarboxylate was
prepared from 8 and 2-nitrobenzenesulfonyl chloride using method
a, followed by saponification with aqueous lioh at 160 °c for
30 min in a microwave reactor to give 2-{[(2-nitrophenyl)sulfonyl]amino}-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid. a solution
thereof (1.4192 g, 3.77 mmol) in methanol (20 ml) was treated
with raney nickel (14.1 g), pressurized to 60 psi with h2 and shaken
for 5 h. the reaction was then filtered, and the filtrate was
concentrated to yield 11a (1.18 g, 90%). ms (esi(+))  xxxd2595xxx /e 332 ( xxxd2595xxx 
+ h)+, 364 ( xxxd2595xxx  + nh4)+, 369 ( xxxd2595xxx  + na)+; ms (esi(-))  xxxd2595xxx /e 345
( xxxd2595xxx  - h)-; 1h nmr (300 mhz, dmso-d6) delta 7.48 (d, 1h), 7.17
(t, 1h), 6.92 (d, 1h), 6.80 (d, 1h), 6.71 (d, 3h), 6.52 (t, 1h), 2.92
( xxxd2595xxx , 2h), 2.58 ( xxxd2595xxx , 2h), 1.60 ( xxxd2595xxx , 4h). anal. (c17h18n2o4s) c, h,
n.
methyl 2-{[(2-aminophenyl)sulfonyl]amino}-5,6,7,8-tetrahydro-1-naphthalenecarboxylate (11b). methyl 2-{[(2-nitrophenyl)sulfonyl]amino}-5,6,7,8-tetrahydro-1-naphthalenecarboxylate was
prepared from 8 and 2-nitrobenzenesulfonyl chloride using method
a. a solution thereof (2.0873 g, 5.35 mmol) in 4:1 methanol/ethyl
acetate (120 ml) was treated with raney nickel (4.00 g), pressurized
to 60 psi with h2 and shaken for 2 h. the reaction was then filtered,
and the filtrate was concentrated to yield 11b (1.8750 g, 97%).
ms (esi(+))  xxxd2595xxx /e 361 ( xxxd2595xxx  + h)+, 383 ( xxxd2595xxx  + na)+; ms (esi(-))
 xxxd2595xxx /e 359 ( xxxd2595xxx  - h)-; 1h nmr (300 mhz, dmso-d6) delta 7.32 (dd,

3842

journal of medicinal chemistry, 2006, vol. 49, no. 13

1h), 7.23 (td, 1h), 7.02 (d, 1h), 6.80 ( xxxd2595xxx , 2h), 6.52 (td, 1h), 3.74
(s, 3h), 2.65 ( xxxd2595xxx , 2h), 2.53 ( xxxd2595xxx , 2h), 1.65 ( xxxd2595xxx , 4h).
methyl 2-({[2-({2-[(2s)-(n-tert-butoxycarbonyl)-pyrrolidin2-yl]ethyl}amino)phenyl]sulfonyl}amino)-5,6,7,8-tetrahydro-1naphthalenecarboxylate (12). a mixture of [(2r)-1-(tert-butoxycarbonyl)-2-pyrrolidinyl]acetic acid (1.004 g, 4.4 mmol) in thf
(10 ml) at -10 °c was treated with nmm (0.484 ml, 4.4 mmol)
and isopropyl chloroformate (0.572 ml, 4.4 mmol), stirred for 30
min, filtered, then added dropwise to a stirred solution of sodium
borohydride (0.37 g, 9.8 mmol) in water (4 ml), and stirred for 1
h. the solution was acidified to ph 4 with 0.1  xxxd2595xxx  hcl, then
transferred to a separatory funnel, and extracted with ethyl acetate.
the organic layer was dried ( xxxd2534xxx ), filtered, and concentrated
to provide the primary alcohol (0.546 g). ms (dci)  xxxd2595xxx /e 216 ( xxxd2595xxx  +
h)+. the intermediate alcohol (0.546 g, 2.5 mmol) in dimethylacetamide (14 ml) was treated with dess-martin periodinane (8.25
ml of 15 wt % solution in ch2cl2, 2.1 mmol), stirred for 15 min,
and filtered. the filtrate was added to a solution of 11b (1.005 g,
2.79 mmol) in ch2cl2/methanol (11 ml), and the resulting mixture
was treated with acetic acid (1.65 ml) and macroporous polystyrenebound cyanoborohydride resin (3.3 g, 7.5 mmol), shaken at 70 °c
for 15 h, filtered, concentrated, and purified by flash chromatography, eluting with 30% ethyl acetate/hexanes. ms (dci)  xxxd2595xxx /e 544
( xxxd2595xxx  + h)+; 1h nmr (300 mhz, dmso-d6) delta 9.50 (br s, 1 h),
7.3-7.4 ( xxxd2595xxx , 2 h), 7.00 ( xxxd2595xxx , 1 h), 6.75 ( xxxd2595xxx , 2 h), 6.52 ( xxxd2595xxx , 1 h),
5.90 ( xxxd2595xxx , 1 h), 3.80 ( xxxd2595xxx , 2 h), 3.75 (s, 3 h), 3.10 ( xxxd2595xxx , 2 h), 2.65 ( xxxd2595xxx ,
2 h), 1.60-1.95 ( xxxd2595xxx , 10 h), 1.40 (s, 9 h).
the boc-protected intermediate was dissolved in ch2cl2 (100
ml), treated with tfa (20 ml), stirred for 1.5 h, and concentrated
to provide 12, which was used as is without purification or
characterization.
methyl 2-[({2-[(4-(piperidinyl)methyl)amino]phenyl}-sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalene carboxylate. compound 9a (1.80 g, 5.0 mmol) and 1-tert-butoxycarbonyl-4(aminomethyl)piperidine (5.0 g, 23.4 mmol) were reacted according
to method b, and the resulting crude 2-[({2-[(4-(n-tert-butoxycarbonyl-piperidinyl)methyl)amino]phenyl}-sulfonyl)amino]-5,6,7,8tetrahydro-1-naphthalene-carboxylic acid was treated with trimethylsilyldiazomethane (3.0 ml of a 2  xxxd2595xxx  solution in hexanes, 6.0
mmol) in 50 ml of 4:1 benzene/methanol for 90 min. the excess
reagent was quenched by the addition of acetic acid and the mixture
shaken in a separatory funnel with etoac and aq nahco3, and
the organics were dried over  xxxd2534xxx . column chromatography
(25% etoac/hexanes) provided 0.59 g of methyl 2-[({2-[(4-(ntert-butoxycarbonyl-piperidinyl)methyl)amino]phenyl}-sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalene carboxylate, which was
dissolved in ch2cl2 (10 ml) and treated with tfa (2 ml) for 150
min. the reaction mixture was shaken in a separatory funnel with
ch2cl2 and ph 7 buffer solution and the organics dried over  xxxd2534xxx 
to provide the title compound. ms (esi)  xxxd2595xxx /e 458 ( xxxd2595xxx  + h)+;1h
nmr (300 mhz, dmso-d6) delta 7.48 (dd, 1h), 7.29 (dt, 1h), 6.90
(d, 1h), 6.75 ( xxxd2595xxx , 2h), 6.57 (t, 1h), 3.71 (s, 3h), 3.24 ( xxxd2595xxx , 2h),
3.03 ( xxxd2595xxx , 2h), 2.81, ( xxxd2595xxx , 2h), 2.62 ( xxxd2595xxx , 4h), 1.82 ( xxxd2595xxx , 3h), 1.65 ( xxxd2595xxx ,
4h), 1.29 ( xxxd2595xxx , 2h).
method c. 2-{[(2-{[(1-isopropyl-4-piperidinyl)methyl]amino}phenyl)sulfonyl]-amino}-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid (13a). a mixture of methyl 2-[({2-[(4-(piperidinyl)methyl)amino]phenyl}-sulfonyl)amino]-5,6,7,8-tetrahydro-1naphthalene carboxylate (0.080 g, 0.18 mmol) in dmf (4 ml) was
treated with acetic acid (0.04 ml) and acetone (0.022 ml, 0.3
mmol). the mixture was shaken at 50 °c for 20 min, treated with
macroporous polystyrene-bound cyanoborohydride resin (85 mg,
0.2 mmol), shaken at 70 °c for 5 h, and filtered. the filtrate was
concentrated, dissolved in 4 ml of 2:1 dioxane/water, treated with
lioh (100 mg, 2.4 mmol), and heated to 160 °c for 30 min in a
microwave reactor. the reaction mixture was concentrated and the
residues purified by c18 reverse-phase hplc using acetonitrile/
water/0.1% tfa to provide the desired product (15 mg). ms (esi(+))  xxxd2595xxx /e 486 ( xxxd2595xxx  + h)+; (esi(-))  xxxd2595xxx /e 484 ( xxxd2595xxx  - h)-; 1h nmr
(300 mhz, dmso-d6) delta 7.51 (dd, 1h), 7.38 (dt, 1h), 6.95 (d, 1h),
6.84 (d, 1h), 6.62 ( xxxd2595xxx , 2h), 6.09 (br t, 1h), 3.52 ( xxxd2595xxx , 2h), 3.12 ( xxxd2595xxx ,

sheppard et al.

3h), 2.89, ( xxxd2595xxx , 2h), 2.66 ( xxxd2595xxx , 4h), 1.90 ( xxxd2595xxx , 3h), 1.67 ( xxxd2595xxx , 4h),
1.42 ( xxxd2595xxx , 2h), 1.22 (d, 6h). anal. (c26h35n3o4s‚2 tfa) c, h, n.
2-({[2-({2-[(2s)-1-(cyclohexylmethyl)-2-pyrrolidinyl]ethyl}amino)phenyl]-sulfonyl}amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid (13b). the title compound was prepared from
12 and cyclohexylcarboxaldehyde using method c. ms (dci)  xxxd2595xxx /e
540 ( xxxd2595xxx  + h)+; 1h nmr (500 mhz, dmso-d6) delta 13.24 (br s,
1h), 9.58 (br s, 1h), 7.55 ( xxxd2595xxx , 1h), 7.41 ( xxxd2595xxx , 1h), 6.92 (d, 1h),
6.84 (d, 1h), 6.66 (br s, 2h), 6.00 (br s, 1h), 3.59 (br s, 1h), 3.05
( xxxd2595xxx , 2h), 2.93 (br s, 2h), 2.71 (br  xxxd2595xxx , 2h), 2.63 (br s, 4h), 2.28 (br
s, 2h), 1.96 ( xxxd2595xxx , 2h), 1.79-1.60 ( xxxd2595xxx , 15h), 1.13 ( xxxd2595xxx , 2h). anal.
(c30h41n3o4s‚tfa) c, h, n.
2-({[2-({2-[(2s)-1-(1-methyl-4-piperidinyl)-2-pyrrolidinyl]ethyl}amino)phenyl]-sulfonyl}amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid (13c). the title compound was prepared
from 12 and 1-methyl-4-piperidone using method c. ms (dci)
 xxxd2595xxx /e 541 ( xxxd2595xxx  + h)+; 1h nmr (500 mhz, dmso-d6) delta 13.24 (br s,
1h), 9.61 (br s, 1h), 7.54 (dd, 1h), 7.42 ( xxxd2595xxx , 1h), 6.97 (d, 1h),
6.86 (d, 1h), 6.67 ( xxxd2595xxx , 2h), 5.93 (br s, 1h), 3.67 (br s, 2h), 3.123.07 ( xxxd2595xxx , 4h), 2.88 (br s, 2h), 2.76 (s, 3h), 2.67 ( xxxd2595xxx , 4h), 2.18 (br
s, 2h), 2.07 ( xxxd2595xxx , 2h), 1.95 ( xxxd2595xxx , 2h), 1.82 (br s, 4h), 1.67 ( xxxd2595xxx , 4h).
anal. (c29h40n4o4s .2 tfa) c, h, n.
2-({[2-({2-[(2s)-1-cyclohexyl-2-pyrrolidinyl]ethyl}amino)phenyl]sulfonyl}amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid (13d). the title compound was prepared from 12 and
cyclohexanone using method c. ms (dci)  xxxd2595xxx /e 526 ( xxxd2595xxx  + h)+; 1h
nmr (500 mhz, dmso-d6) delta 13.20 (br s, 1h), 9.57 (br s, 1h),
7.56 (d, 1h), 7.41 (t, 1h), 6.94 (d, 1h), 6.85 (d, 1h), 6.66 ( xxxd2595xxx ,
2h), 5.96 (br s, 1h), 3.61 (br s, 1h), 3.18-3.08 ( xxxd2595xxx , 3h), 2.682.64 ( xxxd2595xxx , 4h), 2.17 (br s, 2h), 1.92 (br s, 2h), 1.85-1.72 ( xxxd2595xxx , 4h),
1.66 ( xxxd2595xxx , 6h), 1.53 ( xxxd2595xxx , 1h), 1.32-1.01 ( xxxd2595xxx , 5h). anal. (c29h39n3o4s‚
1.5 tfa) c, h, n.
2-({[2-({2-[(2s)-1-isopropyl-2-pyrrolidinyl]ethyl}amino)phenyl]sulfonyl}amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid
(13e). the title compound was prepared from 12 and acetone using
method c. ms (dci)  xxxd2595xxx /e 526 ( xxxd2595xxx  + h)+; 1h nmr (500 mhz,
dmso-d6) delta 13.20 (br s, 1h), 9.57 (br s, 1h), 7.56 (d, 1h), 7.41
(t, 1h), 6.94 (d, 1h), 6.85 (d, 1h), 6.66 ( xxxd2595xxx , 2h), 5.96 (br s, 1h),
3.61 (br s, 1h), 3.18-3.08 ( xxxd2595xxx , 3h), 2.68-2.64 ( xxxd2595xxx , 4h), 2.17 (br
s, 2h), 1.92 (br s, 2h), 1.85-1.72 ( xxxd2595xxx , 4h), 1.66 ( xxxd2595xxx , 6h), 1.53 ( xxxd2595xxx ,
1h), 1.32-1.01 ( xxxd2595xxx , 5h). anal. (c26h35n3o4s‚tfa) c, h, n.
2-{[(2-{[(1-methyl-4-piperidinyl)methyl]amino}phenyl)sulfonyl]amino}-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid (13f).
the title compound was prepared from methyl 2-[({2-[(4-(piperidinyl)methyl)amino]phenyl}-sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalene carboxylate and 37% aqueous formaldehyde using method
c. ms (esi(+))  xxxd2595xxx /e 458 ( xxxd2595xxx  + h)+; (esi(-))  xxxd2595xxx /e 456 ( xxxd2595xxx  - h)-;
1h nmr (300 mhz, dmso-d ) delta 7.51 (dd, 1h), 7.38 (dt, 1h),
6
6.94 (d, 1h), 6.83 (d, 1h), 6.62 ( xxxd2595xxx , 2h), 6.05 (br t, 1h), 3.17 (s,
3h), 3.10 ( xxxd2595xxx , 2h), 2.86 ( xxxd2595xxx , 2h), 2.74 ( xxxd2595xxx , 2h), 2.65 ( xxxd2595xxx , 4h), 1.86
( xxxd2595xxx , 3h), 1.67 ( xxxd2595xxx , 4h), 1.36 ( xxxd2595xxx , 2h). anal. (c24h31n3o4s‚tfa)
c, h, n.
2-{[(2-{[(1′-methyl-1,4′-bipiperidin-4-yl)methyl]amino}phenyl)sulfonyl]amino}-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid
(13 g). the title compound was prepared from methyl 2-[({2-[(4(piperidinyl)methyl)amino]phenyl}-sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalene carboxylate and 1-methyl-4-piperidone using
method c. ms (esi(+))  xxxd2595xxx /e 541 ( xxxd2595xxx  + h)+; (esi(-))  xxxd2595xxx /e 539 ( xxxd2595xxx 
- h)-; 1h nmr (300 mhz, dmso-d6) delta 7.51 (dd, 1h), 7.39 (dt,
1h), 6.96 (d, 1h), 6.84 (d, 1h), 6.62 ( xxxd2595xxx , 2h), 6.09 (br t, 1h), 3.58
( xxxd2595xxx , 2h), 3.51 ( xxxd2595xxx , 2h), 3.34 ( xxxd2595xxx , 1h), 3.12 ( xxxd2595xxx , 2h), 2.97, ( xxxd2595xxx , 4h),
2.78 (s, 3h), 2.66 ( xxxd2595xxx , 4h), 2.25 ( xxxd2595xxx , 2h), 2.00-1.82 ( xxxd2595xxx , 5h), 1.67
( xxxd2595xxx , 4h), 1.42 ( xxxd2595xxx , 2h). anal. (c29h40n4o4s‚3 tfa) c, h, n.
method d. 2-[({2-[(n,n-diethylglycyl)amino]phenyl}sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid (14a).
a solution of 11a (0.0590 g, 0.17 mmol) in ch2cl2 (3.0 ml) was
treated with chloroacetyl chloride (16 µl, 0.20 mmol) and pyridine
(69 µl, 0.85 mmol), stirred for 4 h at room temperature, and then
quenched with 1 n hcl (10 ml). the layers were separated, and
the organic layer was washed with brine, dried ( xxxd2534xxx ), filtered,
and concentrated to a residue (45.0 mg). the residue was dissolved

 xxxd189xxx  sulfonamide  xxxg1400xxx  inhibitors

in acetone (0.4 ml), treated with diethylamine (50 µl, 0.48 mmol),
heated to 60 °c for 2 h, cooled to room temperature, diluted with
etoac (10 ml), and washed with 1 n hcl (10 ml). the organic
layer was dried ( xxxd2534xxx ), filtered, and concentrated. the concentrate
was purified by c18 reverse-phase hplc using acetonitrile/water/
0.1% tfa to provide the desired product (8.7 mg, 18%). ms (esi(+))  xxxd2595xxx /e 460 ( xxxd2595xxx  + h)+; ms (esi(-))  xxxd2595xxx /e 458 ( xxxd2595xxx  - h)-; 1h
nmr (300 mhz, dmso-d6) delta 7.79 ( xxxd2595xxx , 2h), 7.56 ( xxxd2595xxx , 1h), 7.23
( xxxd2595xxx , 2h), 6.90 ( xxxd2595xxx , 1h), 3.30 ( xxxd2595xxx , 4h), 2.80 ( xxxd2595xxx , 2h), 2.73 (s, 2h),
2.59 ( xxxd2595xxx , 2h), 1.61 ( xxxd2595xxx , 4h), 1.06 ( xxxd2595xxx , 6h). anal. (c23h29n3o5s‚
tfa) c, h, n.
2-[({2-[(n,n-diethyl[b]alanyl)amino]phenyl}sulfonyl)amino]5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid (14b). the title
compound was prepared from 11a and 3-chloropropanoyl chloride
using method d. ms (esi(+))  xxxd2595xxx /e 474 ( xxxd2595xxx  + h)+; ms (esi(-))
 xxxd2595xxx /e 472 ( xxxd2595xxx  - h)-; 1h nmr (300 mhz, dmso-d6) delta 7.65 ( xxxd2595xxx ,
2h), 7.55 ( xxxd2595xxx , 1h), 7.22 ( xxxd2595xxx , 2h), 6.89 ( xxxd2595xxx , 1h), 3.38 ( xxxd2595xxx , 2h), 3.17
(q, 4h), 3.08 ( xxxd2595xxx , 2h), 2.80 ( xxxd2595xxx , 2h), 2.57 ( xxxd2595xxx , 2h), 2.55 ( xxxd2595xxx , 4h),
2.43 ( xxxd2595xxx , 2h), 1.75 ( xxxd2595xxx , 2h), 1.57 ( xxxd2595xxx , 4h), 1.27 (t, 6h). anal.
(c24h31n3o5s‚tfa) c, h, n.
2-{[(2-{[4-(diethylamino)butanoyl]amino}phenyl)sulfonyl]amino}-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid (14c).
the title compound was prepared from 11a and 4-chlorobutanoyl
chloride using method d. ms (esi(+))  xxxd2595xxx /e 488 ( xxxd2595xxx  + h)+; ms
(esi(-))  xxxd2595xxx /e 486 ( xxxd2595xxx  - h)-; 1h nmr (300 mhz, dmso-d6) delta
9.73 (s, 1h), 8.15 (d, 1h), 7.79 (dd, 1h), 7.41 (td, 1h), 7.11 (td,
1h), 7.04 (d, 1h), 3.30 ( xxxd2595xxx , 4h), 2.92 ( xxxd2595xxx , 2h), 2.55 ( xxxd2595xxx , 4h), 2.43
( xxxd2595xxx , 2h), 1.75 ( xxxd2595xxx , 2h), 1.57 ( xxxd2595xxx , 4h), 0.98 (t, 6h). anal.
(c25h33n3o5s‚tfa) c, h, n.
2-{[(2-{[4-(1-pyrrolidinyl)butanoyl]amino}phenyl)sulfonyl]amino}-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid (14d).
the title compound was prepared from 11a, 4-chlorobutanoyl
chloride, and pyrrolidine using method d. ms (esi(+))  xxxd2595xxx /e 486
( xxxd2595xxx  + h)+; ms (esi(-))  xxxd2595xxx /e 484 ( xxxd2595xxx  - h)-; 1h nmr (300 mhz,
dmso-d6) delta 9.18 (s, 1h), 8.15 (d, 1h), 7.71 (dd, 1h), 7.62 (ddd,
1h), 7.25 (td, 1h), 6.96 (d, 1h), 6.54 (d, 1h), 3.17 ( xxxd2595xxx , 3h), 3.01
( xxxd2595xxx , 1h), 2.67 ( xxxd2595xxx , 4h), 2.46 ( xxxd2595xxx , 2h), 1.92 ( xxxd2595xxx , 6h), 1.67 ( xxxd2595xxx , 4h).
anal. (c25h31n3o5s‚tfa) c, h, n.
2-{[(2-{[4-(1-piperidinyl)butanoyl]amino}phenyl)sulfonyl]amino}-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid (14e).
the title compound was prepared from 11a, 4-chlorobutanoyl
chloride, and piperidine using method d. ms (esi(+))  xxxd2595xxx /e 500
( xxxd2595xxx  + h)+; ms (esi(-))  xxxd2595xxx /e 498 ( xxxd2595xxx  - h)-; 1h nmr (300 mhz,
dmso-d6) delta 9.19 (s, 1h), 8.15 (d, 1h), 7.71 (dd, 1h), 7.62 (td,
1h), 7.26 (td, 1h), 6.96 (d, 1h), 6.53 (d, 1h), 3.46 ( xxxd2595xxx , 2h), 3.07
( xxxd2595xxx , 2h), 2.87 ( xxxd2595xxx , 2h), 2.67 ( xxxd2595xxx , 4h), 2.46 ( xxxd2595xxx , 2h), 1.94 ( xxxd2595xxx , 2h),
1.79 ( xxxd2595xxx , 2h), 1.67 ( xxxd2595xxx , 7h), 1.40  xxxd2595xxx , 1h). anal. (c26h33n3o5s‚
tfa) c, h, n.
2-[({2-[({[2-(diethylamino)ethyl]amino}carbonyl)amino]phenyl}-sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid (15a). a mixture of 11a (30.2 mg, 0.09 mmol),
triphosgene (8.5 mg, 0.03 mmol), and pyridine (1 ml) was stirred
for 3 h at 70 °c, treated with n,n-diethylethylenediamine (61 µl,
0.44 mmol), stirred for 18 h at 70 °c, concentrated, and purified
by c18 reverse-phase hplc using acetonitrile/water/0.1% tfa to
provide the desired product (2.0 mg, 5%). ms (esi(+))  xxxd2595xxx /e 489
( xxxd2595xxx  + h)+; ms (esi(-))  xxxd2595xxx /e 487 ( xxxd2595xxx  - h)-; 1h nmr (300 mhz,
dmso-d6) delta 8.27 (s, 1h), 8.18 (d, 1h), 7.69 (dd, 1h), 7.53 (td,
1h), 7.47 ( xxxd2595xxx , 1h), 7.10 (t, 1h), 6.95 (d, 1h), 6.65 (s, 1h), 3.19
( xxxd2595xxx , 6h), 2.66 ( xxxd2595xxx , 4h), 1.66 ( xxxd2595xxx , 4h), 1.20 (t, 6h). anal.
(c24h32n4o5s‚tfa) c, h, n.
method e. 2-{[(2-{[({2-[1-methyl-2-pyrrolidinyl]ethyl}amino)carbonyl]amino}-phenyl)sulfonyl]amino}-5,6,7,8-tetrahydro-1naphthalenecarboxylic acid (15b). a solution of 11b (145.6 mg,
0.404 mmol) in thf (0.25 ml) was treated with carbonyldiimidazole (65.5 mg, 0.404 mmol), heated to 50 °c for 1.5 h, cooled
to room temperature, then treated with 2-(2-aminoethyl)-1-methylpyrrolidine (58 µl, 0.404 mmol), stirred for 24 h, and concentrated. the residue was dissolved in pyridine (0.5 ml), treated with
lii (162.2 mg, 1.212 mmol), heated in a microwave reactor at 150
°c for 25 min, concentrated, and purified by c18 reverse-phase

journal of medicinal chemistry, 2006, vol. 49, no. 13 3843

hplc using acetonitrile/water/0.1% tfa to provide 15b. (58.7 mg,
29%). ms (esi(-))  xxxd2595xxx /e 499 ( xxxd2595xxx  - h)-; 1h nmr (300 mhz,
dmso-d6) delta 9.74 (s, 1h), 8.21 ( xxxd2595xxx , 1h), 7.66 (dd, 1h), 7.53 (ddd,
1h), 7.32 (t, 1h), 7.07 (td, 1h), 6.96 (d, 1h), 6.53 (d, 1h), 3.18
( xxxd2595xxx , 3h), 3.01 ( xxxd2595xxx , 2h), 2.78 (s, 3h), 2.66 ( xxxd2595xxx , 4h), 2.30 ( xxxd2595xxx , 2h),
1.92 ( xxxd2595xxx , 2h), 1.67 ( xxxd2595xxx , 4h), 1.28 ( xxxd2595xxx , 1h), 0.87 ( xxxd2595xxx , 1h). anal.
(c25h32n4o5s‚tfa) c, h, n.
2-[({2-[({[2-(1-piperidinyl)ethyl]amino}carbonyl)amino]phenyl}sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid (15c). the title compound was prepared from 11b
and 1-aminoethylpiperidine using method e. ms (esi(+))  xxxd2595xxx /e 501
( xxxd2595xxx  + h)+; ms (esi(-))  xxxd2595xxx /e 499 ( xxxd2595xxx  - h)-; 1h nmr (300 mhz,
dmso-d6) delta 9.89 (s, 1h), 8.27 (s, 1h), 8.21 (dd, 1h), 7.68 (dd,
1h), 7.55 (ddd, 1h), 7.47 (t, 1h), 7.09 (ddd, 1h), 6.95 (d, 1h),
6.60 (d, 1h), 3.50 ( xxxd2595xxx , 2h), 3.45 (g, 2h), 3.16 ( xxxd2595xxx , 2h), 2.91 ( xxxd2595xxx ,
2h), 2.66 ( xxxd2595xxx , 4h), 1.82 ( xxxd2595xxx , 2h), 1.67 ( xxxd2595xxx , 7h), 1.39 ( xxxd2595xxx , 1h). anal.
(c25h32n4o5s‚tfa) c, h, n.
2-[({2-[({[2-(4-morpholinyl)ethyl]amino}carbonyl)amino]phenyl}sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid (15d). the title compound was prepared from 11b
and 4-aminoethylmorpholine using method e. ms (esi(-))  xxxd2595xxx /e
501 ( xxxd2595xxx  - h)-; 1h nmr (300 mhz, dmso-d6) delta 8.21 ( xxxd2595xxx , 2h),
7.68 (dd, 1h), 7.54 ( xxxd2595xxx , 2h), 7.07 (ddd, 1h), 6.94 (d, 1h), 6.77 (d,
1h), 3.84 ( xxxd2595xxx , 4h), 3.46 ( xxxd2595xxx , 4h), 3.24 (t, 4h), 2.67 ( xxxd2595xxx , 4h), 1.65
( xxxd2595xxx , 4h). anal. (c24h30n4o6s‚tfa) c, h, n.
2-[({2-[({[3-(4-morpholinyl)propyl]amino}carbonyl)amino]phenyl}sulfonyl)-amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid (15e). the title compound was prepared from 11b
and 4-(3-aminopropyl)morpholine using method e. ms (esi(+))
 xxxd2595xxx /e 517 ( xxxd2595xxx  + h)+; ms (esi(-))  xxxd2595xxx /e 515 ( xxxd2595xxx  - h)-; 1h nmr
(300 mhz, dmso-d6) delta 8.18 ( xxxd2595xxx , 2h), 7.70 (d, 1h), 7.53 (ddd,
1h), 7.37 ( xxxd2595xxx , 1h), 7.08 (ddd, 1h), 6.95 (d, 1h), 6.63 ( xxxd2595xxx , 1h),
3.93 ( xxxd2595xxx , 2h), 3.39 ( xxxd2595xxx , 2h), 3.12 ( xxxd2595xxx , 6h), 2.67 ( xxxd2595xxx , 4h), 1.82 ( xxxd2595xxx ,
4h). anal. (c25h32n4o6s‚tfa) c, h, n.
2-[({2-[({[3-(1-piperidinyl)propyl]amino}carbonyl)amino]phenyl}sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid (15f). the title compound was prepared from 11b
and 1-(3-aminopropyl)piperidine using method e. ms (esi(+))  xxxd2595xxx /e
515 ( xxxd2595xxx  + h)+; ms (esi(-))  xxxd2595xxx /e 513 ( xxxd2595xxx  - h)-; 1h nmr (300
mhz, dmso-d6) delta 8.18 ( xxxd2595xxx , 2h), 7.69 (dd, 1h), 7.53 (ddd, 1h),
7.34 (s, 1h), 7.08 (ddd, 1h), 6.95 (d, 1h), 6.59 ( xxxd2595xxx , 1h), 3.42 (d,
2h), 3.14 (q, 2h), 3.06 ( xxxd2595xxx , 2h), 2.83 ( xxxd2595xxx , 2h), 2.67 ( xxxd2595xxx , 4h), 1.82
( xxxd2595xxx , 5h), 1.66 ( xxxd2595xxx , 6h), 1.38 ( xxxd2595xxx , 1h). anal. (c26h34n4o5s‚tfa)
c, h, n.
2-({[2-({[2-(diethylamino)ethoxy]carbonyl}amino)phenyl]sulfonyl}amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid
(16). a mixture of 11a (36.7 mg, 0.11 mmol), triphosgene (10.4
mg, 0.033 mmol), and pyridine (1 ml) was stirred for 3 h at 70
°c, treated with 2-(diethylamino)ethanol (70 µl, 0.53 mmol), stirred
for 18 h at 70 °c, concentrated, and purified by c18 reverse-phase
hplc using acetonitrile/water/0.1% tfa to provide the desired
product (4.5 mg, 9%). ms (esi(+))  xxxd2595xxx /e 490 ( xxxd2595xxx  + h)+; ms (esi(-))  xxxd2595xxx /e 488 ( xxxd2595xxx  - h)-; 1h nmr (300 mhz, dmso-d6) delta 8.80
(s, 1h), 8.04 (d, 1h), 7.74 (dd, 1h), 7.64 ( xxxd2595xxx , 1h), 7.24 (t, 1h),
6.97 (d, 1h), 6.65 ( xxxd2595xxx , 1h), 4.40 (t, 2h), 3.20 (q, 6h), 2.56 ( xxxd2595xxx ,
4h), 1.66 ( xxxd2595xxx , 4h), 1.20 (t, 6h). anal. (c24h31n3o6s‚tfa) c, h,
n.
methyl 2-({[2-bromophenyl]sulfonyl}amino)-5,6,7,8-tetrahydro-1-naphthalene-carboxylate (17a). the title compound was
prepared from 8 and 2-bromobenzenesulfonyl chloride using method
a. 1h nmr (400 mhz, cdcl3) delta 8.67 (s, 1 h) 8.09 ( xxxd2595xxx , 1 h);
7.68 ( xxxd2595xxx , 1 h); 7.37 ( xxxd2595xxx , 2 h); 7.25 (d, j ) 8.56 hz, 1 h); 7.00 (d,
j ) 8.56 hz, 1 h); 3.88 (s, 3 h); 2.69 ( xxxd2595xxx , 4 h); 1.68 ( xxxd2595xxx , 4 h).
methyl 2-({[2-bromo-4-fluorophenyl]sulfonyl}amino)-5,6,7,8tetrahydro-1-naphthalene-carboxylate (17b). the title compound
was prepared from 8 and 2-bromo-4-fluorobenzenesulfonyl chloride
using method a. 1h nmr (400 mhz, cdcl3) delta 9.92 (s, 1h), 7.89
( xxxd2595xxx , 2 h) 7.39 (td, 1 h); 7.09 (d, 1 h); 6.86 (d, 1 h); 3.70 (s, 3 h);
2.67 ( xxxd2595xxx , 2 h); 2.53 ( xxxd2595xxx , 2h); 1.66 ( xxxd2595xxx , 4 h).
method f. 2-{[(2-{[2-(diethylamino)ethyl]sulfanyl}phenyl)sulfonyl]amino}-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid

3844

journal of medicinal chemistry, 2006, vol. 49, no. 13

(18a). a suspension of 2-(diethylamino)ethanethiol hydrochloride
(560 mg, 3.30 mmol) and 60% sodium hydride dispersion (224
mg, 10.18 mmol) was stirred in 3 ml of dry dmf until hydrogen
evolution ceased. the mixture was treated with a solution of 17a
(200 mg, 0.55 mmol) in 1 ml of dmf, stirred at 70-75 °c
overnight, concentrated, and dissolved in 2 ml of pyridine. the
mixture was treated with lii (0.221 g, 1.7 mmol), heated in a
microwave reactor at 150 °c for 25 min, and concentrated. the
crude material was purified by c18 reverse-phase hplc using
acetonitrile/water/0.1% tfa to provide the desired product (200
mg, 78.7%). ms (apci)  xxxd2595xxx /e 462.8 ( xxxd2595xxx  + h)+; 1h nmr (400 mhz,
cd3od) delta 7.89 (dd, 1h), 7.65 (dd, 1h), 7.57 (dt, 1h) 7.34 (dt,
1h), 7.18 (d, 1h), 7.00 (d, 1h), 3.34-3.51 ( xxxd2595xxx , 4h), 3.29 ( xxxd2595xxx , 2h),
3.25 (q, 4h), 2.65-2.77 ( xxxd2595xxx , 4h), 1.70 ( xxxd2595xxx , 4h), 1.28 (t, 6h). anal.
(c23h30n2o4s2‚tfa) c, h, n.
2-{[(2-{[3-(diethylamino)propyl]sulfanyl}phenyl)sulfonyl]amino}-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid (18b).
the title compound was prepared from 17a and 3-(diethylamino)propanethiol hydrochloride using method f. ms (apci)  xxxd2595xxx /e 477.3
( xxxd2595xxx  + h)+; 1h nmr (400 mhz, cd3od) delta 7.92 (dd, 1h), 7.59
(dd, 1h), 7.53 (dt, 1h) 7.29 (dt, 1h), 7.17 (d, 1h), 6.99 (d, 1h),
3.27-3.35 ( xxxd2595xxx , 4h), 3.19 ( xxxd2595xxx , 6h), 2.65-2.80 ( xxxd2595xxx , 4h), 2.08 ( xxxd2595xxx ,
2h), 1.70 ( xxxd2595xxx , 4h), 1.26 (t, 6h). anal. (c24h32n2o4s2‚tfa) c, h,
n.
2-{[(2-{[2-(diethylamino)ethyl]sulfanyl}-4-fluorophenyl)sulfonyl]amino}-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid
(18c). the title compound was prepared from 17b and 3-(diethylamino)ethanethiol hydrochloride using method f. ms (esi)  xxxd2595xxx /e
481 ( xxxd2595xxx  + h)+; 1h nmr (400 mhz, cd3od) delta 7.91 (dd, 1h),
7.43 (dd, 1h), 7.05 ( xxxd2595xxx , 2h), 7.04 (d, 1h), 3.41-3.52 ( xxxd2595xxx , 4h),
3.29 (q, 4h), 2.72 ( xxxd2595xxx , 4h), 1.71 ( xxxd2595xxx , 4h), 1.31 (t, 6h). anal.
(c23h29fn2o4s2‚tfa) c, h, n.
2-{[(2-{[2-(dimethylamino)ethyl]sulfanyl}phenyl)sulfonyl]amino}-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid (18d).
the title compound was prepared from 17b and 3-(dimethylamino)ethanethiol hydrochloride using method f. ms (esi)  xxxd2595xxx /e 453 ( xxxd2595xxx 
+ h)+; 1h nmr (300 mhz, dmso-d6) delta 7.55 ( xxxd2595xxx , 1h), 7.50 (dd,
1h), 7.07 ( xxxd2595xxx , 2h), 6.97 (d, 1h), 3.57 ( xxxd2595xxx , 2h), 3.37 ( xxxd2595xxx , 2h), 2.80
(s, 6h), 2.64 ( xxxd2595xxx , 4h), 1.61 ( xxxd2595xxx , 4h). anal. (c21h25fn2o4s2‚tfa)
c, h, n.
2-{[(2-{[2-(dimethylamino)ethyl]sulfanyl}-4-fluorophenyl)sulfonyl]amino}-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid
(18e). the title compound was prepared from 17a and 3-(dimethylamino)ethanethiol hydrochloride using method f. ms (esi)  xxxd2595xxx /e
435 ( xxxd2595xxx  + h)+; 1h nmr (300 mhz, dmso-d6) delta 7.56 (d, 1h),
7.50 (dd, 1h), 7.44 (d, 1h), 7.24 (d, 1h), 7.14 ( xxxd2595xxx , 1h), 6.92 (d,
1h), 3.57 ( xxxd2595xxx , 2h), 3.32 ( xxxd2595xxx , 2h), 2.77 (s, 6h), 2.63 ( xxxd2595xxx , 4h), 1.58
( xxxd2595xxx , 4h). anal. (c21h26n2o4s2‚tfa) c, h, n.
method g. 2-{[(2-{[2-(diethylamino)ethyl]sulfinyl}phenyl)sulfonyl]amino}-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid
(19a). a sample of 18a (0.091 g, 0.20 mmol) was dissolved in 2.5
ml of glacial acetic acid. to this was added 650 mg of 30%
 xxxd2298xxx  solution. after stirring at room temperature for
8.3 h, the reaction mixture was concentrated and purified by c18
reverse-phase hplc using acetonitrile/water/0.1% tfa to provide
the desired product (45 mg, 47.8%). ms (apci):  xxxd2595xxx /e 479.1 ( xxxd2595xxx  +
h)+; 1h nmr (400 mhz, cd3od) delta 8.13 (dd, 1h), 7.90 (dt, 1h),
7.84 (dd, 1h) 7.70 (dt, 1h), 7.09 (d, 1h), 6.98 (d, 1h), 3.60-3.73
( xxxd2595xxx , 2h), 3.42-3.50 ( xxxd2595xxx , 1h), 3.23-3.32 ( xxxd2595xxx , 4h), 3.01-3.10 ( xxxd2595xxx ,
1h), 2.66-2.78 ( xxxd2595xxx , 4h), 1.65-1.80 ( xxxd2595xxx , 4h), 1.31 (t, 6h). anal.
(c23h30n2o5s2‚1.5 tfa) c, h, n.
2-{[(2-{[2-(diethylamino)ethyl]sulfinyl}-4-fluorophenyl)sulfonyl]amino}-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid
(19b). the title compound was prepared from 18c using method
g. ms (esi)  xxxd2595xxx /e 497 ( xxxd2595xxx  + h)+; 1h nmr (400 mhz, dmso-d6)
delta 7.79 ( xxxd2595xxx , 2h), 7.58 ( xxxd2595xxx , 1h), 7.02 (d, 1h), 6.82 (d, 1h), 3.40 ( xxxd2595xxx ,
2h), 3.14 ( xxxd2595xxx , 2h), 3.07 (q, 4h), 2.68 ( xxxd2595xxx , 4h), 1.60 ( xxxd2595xxx , 4h), 1.15
(t, 6h). anal. (c23h29fn2o5s2‚tfa‚h2o) c, h, n.
2-{[(2-{[2-(dimethylamino)ethyl]sulfinyl}-4-fluorophenyl)sulfonyl]amino}-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid
(19c). the title compound was prepared from 18d using method

sheppard et al.

g. ms (esi)  xxxd2595xxx /e 469 ( xxxd2595xxx  + h)+; 1h nmr (300 mhz, dmso-d6)
delta 7.87 (dd, 1h), 7.78 (dd, 1h), 7.64 (td, 1h), 7.06 (d, 1h), 6.69
(d, 1h), 3.54-3.44 ( xxxd2595xxx , 2h), 3.24-3.04 ( xxxd2595xxx , 2h), 2.77 (s, 6h), 2.70
( xxxd2595xxx , 2h), 2.62 ( xxxd2595xxx , 2h), 1.68 ( xxxd2595xxx , 4h). anal. (c21h25fn2o5s2‚tfa)
c, h, n.
2-{[(2-{[2-(dimethylamino)ethyl]sulfinyl}phenyl)sulfonyl]amino}-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid (19d).
the title compound was prepared from 18e using method g. ms
(esi)  xxxd2595xxx /e 451 ( xxxd2595xxx  + h)+; 1h nmr (300 mhz, dmso-d6) delta 8.09
(dd, 1h), 7.96 (td, 1h), 7.86-7.76 ( xxxd2595xxx , 2h), 7.02 (d, 1h), 6.62 (d,
1h), 3.52-3.43 ( xxxd2595xxx , 2h), 3.24-3.01 ( xxxd2595xxx , 2h), 2.78 (s, 6h), 2.69
( xxxd2595xxx , 2h), 2.64 ( xxxd2595xxx , 2h), 1.67 ( xxxd2595xxx , 4h). anal. (c21h26n2o5s2‚1.5 tfa)
c, h, n.
2-[({2-[3-(diethylamino)propoxy]phenyl}sulfonyl)amino]5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid (20a). the title
compound was prepared from 17a and 3-diethylamino- xxxd3026xxx 
using method f. ms (apci):  xxxd2595xxx /e 461 ( xxxd2595xxx  + h)+; 1h nmr (400
mhz, cd3od) delta 7.74 (dd, 1h), 7.54 (dt, 1h), 7.27 (d, 1h) 7.12
(d, 1h), 6.98-7.04 ( xxxd2595xxx , 2h), 4.27 (t, 2h), 3.43-3.51 ( xxxd2595xxx , 2h), 3.253.36 ( xxxd2595xxx , 6h), 3.65-3.81 ( xxxd2595xxx , 4h), 3.35 ( xxxd2595xxx , 2h), 1.70 ( xxxd2595xxx , 4h),
1.37 (t, 6h). anal. (c23h30n2o5s‚1.25 tfa) c, h, n.
2-[({2-[2-(1-methylpyrrolidin-2-yl)ethoxy]phenyl}sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid (20b).
the title compound was prepared from 17a and 2-(2-hydroxyethyl)1-methylpyrrolidine using method f. ms (apci):  xxxd2595xxx /e 459 ( xxxd2595xxx  +
h)+; 1h nmr (400 mhz, cdcl3) delta 7.93 (dd, 1h), 7.44 (dt, 1h),
7.38 (d, 1h) 7.02-9.97 ( xxxd2595xxx , 2h), 6.87 (d, 1h), 4.32 ( xxxd2595xxx , 1h), 4.053.80 ( xxxd2595xxx , 7h), 3.77 ( xxxd2595xxx , 1h), 3.15 (s, 3h), 2.85 ( xxxd2595xxx , 1h), 2.63 ( xxxd2595xxx ,
1h), 2.39 ( xxxd2595xxx , 1h), 2.25-2.10 ( xxxd2595xxx , 2h), 2.00 ( xxxd2595xxx , 1h), 1.73 ( xxxd2595xxx ,
2h), 1.60 ( xxxd2595xxx , 2h). anal. (c24h30n2o5s‚tfa) c, h, n.
methyl 2-({[2-(methoxycarbonyl)phenyl]sulfonyl}amino)5,6,7,8-tetrahydro-1-naphthalenecarboxylate (21). the title compound was prepared from 8 and methyl 2-(chlorosulfonyl)benzoate
using method a. ms (esi(+))  xxxd2595xxx /e 404 ( xxxd2595xxx  + h)+; 480 ( xxxd2595xxx  + na)+;
(esi(-))  xxxd2595xxx /e 402 ( xxxd2595xxx  - h)-; 1h nmr (300 mhz, dmso-d6) delta
9.14 (s, 1h), 7.77-7.65 ( xxxd2595xxx , 4h), 7.12 (d, 1h), 6.98 (d, 1h), 3.01
(s, 3h), 3.63 (s, 3h), 2.68 (br s, 2h), 2.53 (br s, 2h), 1.66 (br  xxxd2595xxx ,
4h).
2-({[1-(methoxycarbonyl)-5,6,7,8-tetrahydro-2-naphthalenyl]amino}sulfonyl)- xxxd306xxx  (22). a solution of 21 (3.04 g, 7.54
mmol) in methanol (70 ml) and distilled water (7.8 ml) was treated
with lithium hydroxide monohydrate (1.58 g, 37.7 mmol), heated
to 60 °c overnight, cooled to room temperature, treated with 1 n
hcl, and concentrated. the aqueous layer was washed twive with
dichloromethane, and the combined organic phases were dried
( xxxd2534xxx ), filtered, and concentrated to provide the desired product.
ms (esi(+))  xxxd2595xxx /e 388 ( xxxd2595xxx  + h)+; 1h nmr (300 mhz, dmso-d6)
delta 14.00 (br s, 1h), 8.85 (br s, 1h), 7.83 (d, 1h), 7.73 ( xxxd2595xxx , 2h),
7.64 ( xxxd2595xxx , 1h), 7.13 (s, 2h), 3.63 (s, 3h), 2.67 (br s, 2h), 2.51 (br
s, 2h), 1.65 (br  xxxd2595xxx , 4h).
method h. 2-({[2-({[2-(diethylamino)ethyl]amino}carbonyl)phenyl]sulfonyl}-amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid (23a). a solution of 22 (100 mg, 0.257 mmol) in
dimethylformamide (2.0 ml) was treated with 4-methylmorpholine
(109 µl, 0.992 mmol) and o-(7-azabenzotriazol-1-yl)-n,n,n′,n′tetramethyluronium hexafluorophosphate (188.5 mg, 0.496 mmol),
stirred for 1 h at room temperature, treated with n,n-diethylethylenediamine (72 µl, 0.514 mmol), stirred overnight at room
temperature, and treated with 1 n hcl. the aqueous layer was
washed twice with dichloromethane, and the combined organic
phases were dried ( xxxd2534xxx ), filtered, and concentrated. the resulting
residue was purified by preparative hplc to provide the methyl
ester. ms (esi(+))  xxxd2595xxx /e 488 ( xxxd2595xxx  + h)+; (esi(-))  xxxd2595xxx /e 486 ( xxxd2595xxx  h)-; 1h nmr (300 mhz, dmso-d6) delta 9.10 (br s, 1h), 9.06 (t,
1h), 9.84 (s, 1h), 7.77 (dt, 1h), 7.68 (dd, 2h), 7.62 ( xxxd2595xxx , 1h), 7.12
(d, 1h), 7.08 (d, 1h), 3.64 ( xxxd2595xxx , 2h), 3.63 (s, 3h), 3.29-3.22 ( xxxd2595xxx ,
6h), 2.68 (br s, 2h), 2.51 (br s, 2h), 1.65 (br  xxxd2595xxx , 4h), 1.24 (t, 6h).
a sample of the intermediate ester (13.8 mg, 0.028 mmol),
dioxane (0.5 ml), distilled water (0.25 ml), and lithium hydroxide
monohydrate (12.0 mg, 0.283 mmol) was sealed in a 2 ml
microwave reaction vessel and heated in a microwave for 1200 s

 xxxd189xxx  sulfonamide  xxxg1400xxx  inhibitors

at 160 °c. the solution was cooled to room temperature, treated
with 1 n hcl, and concentrated. the resulting residue was purified
by preparative hplc to provide the desired product. ms (esi(+))
 xxxd2595xxx /e 474 ( xxxd2595xxx  + h)+; (esi(-))  xxxd2595xxx /e 472 ( xxxd2595xxx  - h)-; 1h nmr (300
mhz, dmso-d6) delta 13.20 (br s, 1h), 9.14 (br s, 1h), 9.02 (t, 2h),
7.77 ( xxxd2595xxx , 2h), 7.65 ( xxxd2595xxx , 2h), 7.04 (d, 1h), 6.93 (d, 1h), 3.63 (q,
1h), 3.25 ( xxxd2595xxx , 6h), 2.67 (br s, 2h), 2.61 (br s, 2h), 1.66 (br s, 4h),
1.23 (t, 6h). anal. (c24h31n3o5s‚tfa) c, h, n.
2-[({2-[({2-[1-methyl-2-pyrrolidinyl]ethyl}amino)carbonyl]phenyl}sulfonyl)-amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid (23b). the title compound was prepared from 22 and
2-(2-aminoethyl)-1-methylpyrrolidine using method h. ms (esi(+))  xxxd2595xxx /e 486 ( xxxd2595xxx  + h)+; (esi(-))  xxxd2595xxx /e 484 ( xxxd2595xxx  - h)-; 1h nmr
(300 mhz, dmso-d6) delta 13.15 (br s, 1h), 9.46 (br s, 1h), 9.00 (s,
1h), 8.89 (t, 1h), 7.75 (dd, 2h), 7.62 ( xxxd2595xxx , 2h), 7.02 (d, 1h), 6.92
(d, 1h), 3.57 ( xxxd2595xxx , 2h), 3.32 ( xxxd2595xxx , 3h), 3.06 (quint, 1h), 2.81 (d,
3h), 2.65 (s, 2h), 2.60 (s, 2h), 2.37 ( xxxd2595xxx , 1h), 2.16 ( xxxd2595xxx , 1h), 1.99
( xxxd2595xxx , 1h), 1.90 ( xxxd2595xxx , 1h), 1.70 ( xxxd2595xxx , 1h) 1.65 (s, 4h). anal.
(c25h31n3o5s‚tfa) c, h, n.
2-({[2-({[2-(1-piperidinyl)ethyl]amino}carbonyl)phenyl]sulfonyl}amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid
(23c). the title compound was prepared from 22 and 1-(2aminoethyl)piperidine using method h. ms (esi(+))  xxxd2595xxx /e 486 ( xxxd2595xxx 
+ h)+; (esi(-))  xxxd2595xxx /e 484 ( xxxd2595xxx  - h)-; 1h nmr (300 mhz, dmsod6) delta 9.02 (br  xxxd2595xxx , 2h), 7.78 ( xxxd2595xxx , 2h), 7.64 ( xxxd2595xxx , 2h), 7.04 (d, 1h),
6.93 (d, 1h), 3.66 (q, 3h), 3.26 (t, 3h), 2.98 (br s, 2h), 2.67 (br s,
2h), 2.61 (br s, 2h), 1.83 (br  xxxd2595xxx , 2h), 1.66 (t, 7h), 1.40 (br s, 1h).
anal. (c25h31n3o5s‚tfa) c, h, n.
2-({[2-({[3-(diethylamino)propyl]amino}carbonyl)phenyl]sulfonyl}amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid
(23d). the title compound was prepared from 22 and 3-(n,ndiethylamino)propylamine using method h. ms (esi(+))  xxxd2595xxx /e 488
( xxxd2595xxx  + h)+, 510 ( xxxd2595xxx  + na)+; (esi(-))  xxxd2595xxx /e 486 ( xxxd2595xxx  - h)-; 1h nmr
(300 mhz, dmso-d6) delta 13.14 (br s, 1h), 9.01 (s, 2h), 8.92 (t,
1h), 7.75 (dt, 2h), 7.63 (dd, 2h), 7.03 (d, 1h), 6.92 (d, 1h), 3.39
(q, 2h), 3.14 ( xxxd2595xxx , 6h), 2.66 (br s, 2h), 2.61 (br s, 2h), 1.89 ( xxxd2595xxx ,
2h), 1.20 (t, 6h). anal. (c25h33n3o5s‚1.66 tfa) c, h, n.
2-({[2-({[4-(diethylamino)butyl]amino}carbonyl)phenyl]sulfonyl}amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid
(23e). the title compound was prepared from 22 and 4-(n,ndiethylamino)butylamine using method h. ms (esi(+))  xxxd2595xxx /e 502
( xxxd2595xxx  + h)+; (esi(-))  xxxd2595xxx /e 500 ( xxxd2595xxx  - h)-; 1h nmr (300 mhz,
dmso-d6) delta 13.11 (br s, 1h), 9.03 (s, 1h), 8.93 (br s, 1h), 8.86
(t, 1h), 7.74 (dt, 2h), 7.62 (dd, 2h), 7.03 (d, 1h), 6.90 (d, 1h),
3.58 ( xxxd2595xxx , 2h), 3.33 (q, 2h), 3.12 ( xxxd2595xxx , 4h), 2.66 (br s, 2h), 2.60 (br
s, 2h), 1.74-1.56 ( xxxd2595xxx , 8h), 1.20 (t, 6h). anal. (c26h35n3o5s‚tfa)
c, h, n.
2-({[2-({[(4-(diethylamino)-1-methylbutyl]amino}carbonyl)4-fluorophenyl]-sulfonyl}amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid (23f). in a high-pressure vessel was placed
17b (1.26 g, 2.85 mmol), thf (12 ml), triethylamine (6 ml), n-(4aminopentyl)-n,n-diethylamine (4.5 g, 28.4 mmol), and pdcl2(dppf)‚
ch2cl2 (233 mg). the solution was stirred at 120 °c under 450
psi carbon monoxide for 16 h, cooled to room temperature, and
filtered. the filtrate was treated with 1 n hcl, and the aqueous
layer was extracted twice with ethyl acetate. the combined organic
fractions were dried ( xxxd2534xxx ), filtered, and concentrated. the
resulting residue was purified by preparative hplc to provide
methyl 2-({[2-({[4-(diethylamino)-1-methylbutyl]amino}carbonyl)4-fluorophenyl]sulfonyl}amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylate (1.16 g, 74%). ms (esi(+))  xxxd2595xxx /e 548 ( xxxd2595xxx  + h)+;
(esi(-))  xxxd2595xxx /e 546 ( xxxd2595xxx  - h)-; 1h nmr (300 mhz, dmso-d6) delta
8.93 (br s, 1h), 8.87 (s, 1h), 8.82 (d, 1h), 7.70 (dd, 1h), 7.53 (dt,
1h), 7.12 (d, 1h), 7.06 (d, 1h), 4.02 ( xxxd2595xxx , 2h), 3.18-3.02 ( xxxd2595xxx , 6h),
2.68 (br s, 2h), 2.51 (br s, 2h), 1.75-163 (br  xxxd2595xxx , 5h), 1.55 ( xxxd2595xxx ,
2h), 1.20 ( xxxd2595xxx , 9h).
methyl 2-({[2-({[4-(diethylamino)-1-methylbutyl]amino}carbonyl)4-fluorophenyl]-sulfonyl}amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylate (1.16 g, 2.12 mmol), pyridine (20 ml), and lithium
iodide (0.849 g, 6.34 mmol) were combined and heated in a
microwave reactor for 1500 s at 160 °c. the solution was cooled

journal of medicinal chemistry, 2006, vol. 49, no. 13 3845

to room temperature, treated with 1 n hcl, and concentrated. the
resulting residue was purified by preparative hplc to provide 23f
(0.459 g, 41%). ms (esi(+))  xxxd2595xxx /e 534 ( xxxd2595xxx  + h)+; (esi(-))  xxxd2595xxx /e
532 ( xxxd2595xxx  - h)-; 1h nmr (300 mhz, dmso-d6) delta 13.13 (br s,
1h), 9.45 (br s, 1h), 8.96 (br s, 2h), 8.74 (d, 1h), 7.78 (dd, 1h),
7.50-7.42 ( xxxd2595xxx , 2h), 7.04 (d, 1h), 6.92 (d, 1h), 4.02 ( xxxd2595xxx , 1h), 3.183.02 ( xxxd2595xxx , 6h), 2.67 (br s, 2h), 2.60 (br s, 2h), 1.74-163 (br  xxxd2595xxx ,
6h), 1.52 ( xxxd2595xxx , 2h), 1.19 ( xxxd2595xxx , 9h). anal. (c27h36fn3o5s‚tfa) c,
h, n.
2-({[2-({[(4-(diethylamino)-1-methylbutyl]amino}carbonyl)phenyl]sulfonyl}-amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid (23g). the title compound was prepared from 22 and
n-(4-aminopentyl)-n,n-diethylamine using method h. ms (esi(+))  xxxd2595xxx /e 516 ( xxxd2595xxx  + h)+, 538 ( xxxd2595xxx  + na)+; (esi(-))  xxxd2595xxx /e 514 ( xxxd2595xxx  h)-; 1h nmr (300 mhz, dmso-d6) delta 9.18 (br s, 1h), 9.02 (br s,
1h), 8.70 (d, 1h), 7.74 (dt, 2h), 7.61 ( xxxd2595xxx , 2h), 7.02 (d, 1h), 6.89
(d, 1h), 4.04 (quint, 1h), 3.17-3.00 ( xxxd2595xxx , 6h), 2.66 (br s, 2h), 2.61
(br s, 2h), 1.72 ( xxxd2595xxx , 2h), 1.66 (s, 4h), 1.54 (q, 2h), 1.20 ( xxxd2595xxx , 9h).
anal. (c27h37n3o5s‚tfa) c, h, n.
method i. 2-[({2-[(1z)-3-(diethylamino)-1-propenyl]phenyl}sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid
(24a). a solution of 17a (0.212 g, 0.5 mmol), (z)-tributyl-(3(dimethylamino)-prop-1-enyl)stannane (0.245 g, 0.6 mmol), and bis(tri-tert-butylphosphine)palladium (0.050 g, 0.1 mmol) in 2 ml of
degassed toluene was heated under ar at 90 °c for 90 min. the
mixture was concentrated, chromatographed on silica (0:15%
triethylamine/etoac), and the product recrystallized from hot 4:1
heptane/etoac to give a tan solid (0.153 g, 67%). 1h nmr (400
mhz, cdcl3) delta 8.02 (d, j ) 7.96 hz, 1h), 7.50 (t, j ) 7.48 hz,
1h), 7.37 (t, j ) 7.62 hz, 1h), 7.31 (d, j ) 7.27 hz, 1h), 6.97
( xxxd2595xxx , 3h), 5.97 ( xxxd2595xxx , 1h), 3.83 (s, 3h), 3.01 (d, j ) 6.59 hz, 2h),
2.70 ( xxxd2595xxx , 4h), 2.41 (q, j ) 7.09 hz, 4h), 1.70 ( xxxd2595xxx , 4h), 0.87 (t, j
) 7.14 hz, 6h).
the intermediate methyl ester (0.116 g, 0.25 mmol) and lithium
iodide (0.134 g, 1.0 mmol) in pyridine (7 ml) were heated in a
microwave reactor at 150 °c for 35 min and then concentrated in
vacuo. the crude product was purified by c18 reverse-phase hplc
using acetonitrile/water/0.1% tfa to provide the desired product
(0.085 g, 77%). ms (esi(+))  xxxd2595xxx /e 443 ( xxxd2595xxx  + h)+; ms (esi(-))
 xxxd2595xxx /e 441 ( xxxd2595xxx  - h)-; 1h nmr (400 mhz, dmso-d6) delta 9.75 (s,
1h), 9.53 (s, 1h), 7.81 (dd, j ) 7.89, 1.17 hz, 1h), 7.66 (td, j )
7.55, 1.10 hz, 1h), 7.51 (t, j ) 7.34 hz, 1h), 7.33 ( xxxd2595xxx , 2h), 6.97
(d, j ) 8.23 hz, 1h), 6.66 (d, j ) 8.37 hz, 1h), 5.89 (dt, j )
11.66, 6.93 hz, 1h), 3.80 (d, j ) 6.45 hz, 2h), 3.05 (q, j ) 7.23
hz, 4h), 2.66 ( xxxd2595xxx , 4h), 1.65 ( xxxd2595xxx , 4h), 1.02 (t, j ) 7.20 hz, 6h).
anal. (c24h30n2o4s‚hcl‚0.25 h2o) c, h, n.
2-[({2-[(1z)-3-(diethylamino)-1-propenyl]-4-fluorophenyl}sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid
(24b). the title compound was prepared from 17b and n,n-diethyln-[(2z)-3-(tributylstannyl)-2-propenyl]amine using method i. ms
(esi(+))  xxxd2595xxx /e 461 ( xxxd2595xxx  + h)+; ms (esi(-))  xxxd2595xxx /e 459 ( xxxd2595xxx  - h)-; 1h
nmr (400 mhz, dmso-d6) delta 10.79 (s, 1h), 9.81 (s, 1h), 7.82
( xxxd2595xxx , 1h), 7.37-7.23 ( xxxd2595xxx , 3h), 7.02 (d, 1h), 6.71 (d, 1h), 6.11 ( xxxd2595xxx ,
1h), 3.83 ( xxxd2595xxx , 2h), 3.02 (q, 4h), 2.65 ( xxxd2595xxx , 4h), 1.67 ( xxxd2595xxx , 4h), 1.09
(t, 6h). anal. (c24h29fn2o4s‚tfa) c, h, n.
2-[({2-[(1z)-4-(diethylamino)-1-butenyl]phenyl}sulfonyl)amino]5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid (24c). the title
compound was prepared from 17a and n,n-diethyl-n-[(3z)-4(tributylstannyl)-3-butenyl]amine using method i. ms (esi(+))  xxxd2595xxx /e
457 ( xxxd2595xxx  + h)+; ms (esi(-))  xxxd2595xxx /e 455 ( xxxd2595xxx  - h)-; 1h nmr (400
mhz, dmso-d6) delta 7.83 (d, j ) 7.82 hz, 1h), 7.62 (t, j ) 8.16
hz, 1h), 7.45 (t, j ) 7.75 hz, 1h), 7.39 (d, j ) 7.55 hz, 1h),
6.97 ( xxxd2595xxx , 2h), 6.73 (d, j ) 8.10 hz, 1h), 5.73 ( xxxd2595xxx , 1h), 3.09 ( xxxd2595xxx ,
2h), 3.02 (q, j ) 7.18 hz, 4h), 2.65 ( xxxd2595xxx , 4h), 2.40 ( xxxd2595xxx , 2h), 1.64
( xxxd2595xxx , j ) 3.02, 3.02 hz, 4h), 1.09 (t, j ) 7.27 hz, 6h). anal.
(c25h32n2o4s‚1.4 tfa) c, h, n.
2-[({2-[(1z)-5-(diethylamino)-1-pentenyl]phenyl}sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid (24d).
the title compound was prepared from 17a and n,n-diethyl-n[(4z)-5-(tributylstannyl)-4-pentenyl]amine using method i. ms
(esi(+))  xxxd2595xxx /e 471 ( xxxd2595xxx  + h)+; ms (esi(-))  xxxd2595xxx /e 469 ( xxxd2595xxx  - h)-; 1h

3846

journal of medicinal chemistry, 2006, vol. 49, no. 13

nmr (400 mhz, dmso-d6) delta 7.79 (dd, j ) 7.83, 1.22 hz, 1h),
7.48 (td, j ) 7.46, 1.22 hz, 1h), 7.32 ( xxxd2595xxx , 2h), 7.12 (d, j ) 8.31
hz, 1h), 6.93 (d, j ) 11.74 hz, 1h), 6.79 (d, j ) 8.31 hz, 1h),
5.71 (dt, j ) 11.55, 7.06 hz, 1h), 2.90 ( xxxd2595xxx , 2h), 2.68 (q, j ) 7.09
hz, 4h), 2.58 ( xxxd2595xxx , 4h), 2.10 ( xxxd2595xxx , 2h), 1.56 ( xxxd2595xxx , 6h), 0.99 (t, j )
7.21 hz, 6h). anal. (c26h34n2o4s‚tfa) c, h, n.
2-[({2-[(1z)-3-(1-pyrrolidino)-1-butenyl]phenyl}sulfonyl)amino]5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid (24e). the title
compound was prepared from 17a and (z)-3-(1-pyrrolidinyl)-1butenyl-tributylstannane using method i. ms (apci) 455 ( xxxd2595xxx  +
h)+; 1h nmr (400 mhz, dmso-d6) delta 9.77 (s, 2 h); 7.83 (dd, j
) 7.82, 1.10 hz, 1 h); 7.66 (td, j ) 7.58, 1.30 hz, 1 h); 7.52 (td,
j ) 7.72, 1.03 hz, 1 h); 7.30 (d, j ) 7.41 hz, 1 h); 7.18 (d, j )
11.53 hz, 1 h); 6.97 (d, j ) 8.37 hz, 1 h); 6.65 (d, j ) 8.23 hz,
1 h); 5.80 (dd, j ) 11.53, 10.43 hz, 1 h); 3.98 (s, 1 h); 2.99 (s,
1 h); 2.74 (s, 1 h); 2.65 (s, 4 h); 1.88 (s, 1 h); 1.76 (s, 3 h); 1.65
( xxxd2595xxx , 4 h); 1.43 (d, j ) 6.45 hz, 3 h). anal. (c25h30n2o4s‚tfa‚
h2o) c, h, n.
2-[({2-[(1z)-3-(1-pyrrolidino)-1-butenyl]-4-fluorophenyl}sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid
(24f). the title compound was prepared from 17b and (z)-3-(1pyrrolidinyl)-1-butenyl-tributylstannane using method i. ms (apci)
473 ( xxxd2595xxx  + h)+; 1h nmr (400 mhz, dmso-d6) delta 7.90 (dd, 1h),
7.20 (dt, 1h), 7.10-7.02 ( xxxd2595xxx , 4h), 5.87 (t, 1h), 3.50 ( xxxd2595xxx , 2h), 3.30
( xxxd2595xxx , 1h), 3.06 ( xxxd2595xxx , 1h), 2.87 ( xxxd2595xxx , 1h), 2.73 ( xxxd2595xxx , 4h), 2.05-1.85 ( xxxd2595xxx ,
4h), 1.72 ( xxxd2595xxx , 4h), 1.54 (d, 3h). anal. (c25h29fn2o4s‚tfa) c,
h, n.
2-[({2-[(1z)-3-(diethylamino)-1-butenyl]phenyl}sulfonyl)amino]5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid (24g). the title
compound was prepared from 17a and (z)-3-(triethylamino)-1butenyl-tributylstannane using method i. ms (apci) 457 ( xxxd2595xxx  +
h)+; 1h nmr (400 mhz, dmso-d6) delta 10.16 (s, 1 h); 9.81 (s, 1
h); 7.81 (dd, j ) 7.96, 1.10 hz, 1 h); 7.67 (td, j ) 7.55, 1.24 hz,
1 h); 7.51 (t, j ) 7.27 hz, 1 h); 7.34 (d, j ) 7.41 hz, 1 h); 7.24
(d, j ) 11.66 hz, 1 h); 6.98 (d, j ) 8.23 hz, 1 h); 6.66 (d, j )
8.23 hz, 1 h); 5.91 (t, j ) 11.11 hz, 1 h); 3.00 ( xxxd2595xxx , 2 h); 2.85 ( xxxd2595xxx ,
1 h); 2.64 ( xxxd2595xxx , 4 h); 1.66 ( xxxd2595xxx , 4 h); 1.53 (d, j ) 6.45 hz, 3 h);
1.03 (t, j ) 7.14 hz, 3 h); 0.89 (t, j ) 7.00 hz, 3 h). anal.
(c25h32n2o4s‚tfa‚h2o) c, h, n.
2-[({2-[(1z)-3-(diethylamino)-1-butenyl]-4-fluorophenyl}sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid
(24h). the title compound was prepared from 17b and (z)-3(diethylamino)-1-butenyl-tributylstannane using method i. 1h nmr
(400 mhz, meoh-d4) delta 7.90 (dd, j ) 8.92, 5.49 hz, 1 h); 7.22
(td, j ) 8.47, 2.54 hz, 1 h); 7.00-7.17 ( xxxd2595xxx , 4 h); 5.86 (t, j )
11.20 hz, 1 h); 4.15-4.31 ( xxxd2595xxx , 1 h); 3.35-3.45 ( xxxd2595xxx , 1 h); 3.103.27 ( xxxd2595xxx , 3 h); 2.98-3.09 ( xxxd2595xxx , 1 h); 2.66-2.80 ( xxxd2595xxx , 4 h); 1.661.81 ( xxxd2595xxx , 4 h); 1.11-1.23 ( xxxd2595xxx , 3 h); 0.99-1.12 ( xxxd2595xxx , 3 h). anal.
(c25h31fn2o4s‚1.2 tfa) c, h, n.
2-[({2-[(1e)-3-(diethylamino)-1-propenyl]phenyl}sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid (25a).
the title compound was prepared from 17a and n,n-diethyl-n[(2e)-3-(tributylstannyl)-2-propenyl]amine using method i. ms
(esi(+))  xxxd2595xxx /e 443 ( xxxd2595xxx  + h)+; ms (esi(-))  xxxd2595xxx /e 441 ( xxxd2595xxx  - h)-; 1h
nmr (400 mhz, dmso-d6) delta 9.80 (s, 1h), 9.53 (s, 1h), 7.78 ( xxxd2595xxx ,
2h), 7.64 ( xxxd2595xxx , 1h), 7.55 (d, j ) 15.51 hz, 1h), 7.47 ( xxxd2595xxx , 1h), 6.94
(d, j ) 8.23 hz, 1h), 6.60 (d, j ) 8.10 hz, 1h), 6.27 (ddd, j )
15.23, 7.48, 7.20 hz, 1h), 3.87 (d, j ) 7.00 hz, 2h), 3.16 (q, j )
6.82 hz, 4h), 2.64 (d, j ) 4.53 hz, 4h), 1.65 ( xxxd2595xxx , 4h), 1.22 (t, j
) 7.27 hz, 6h). anal. (c24h30n2o4s‚1.1 tfa) c, h, n.
2-[({2-[(1e)-4-(diethylamino)-1-butenyl]phenyl}sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid (25b).
the title compound was prepared from 17a and n,n-diethyl-n[(3e)-4-(tributylstannyl)-3-butenyl]amine using method i. ms (esi(+))  xxxd2595xxx /e 457 ( xxxd2595xxx  + h)+; ms (esi(-))  xxxd2595xxx /e 455 ( xxxd2595xxx  - h)-; 1h
nmr (400 mhz, dmso-d6) delta 7.75 (dd, j ) 7.96, 1.37 hz, 1h),
7.67 ( xxxd2595xxx , 1h), 7.58 (t, j ) 7.96 hz, 1h), 7.37 (t, j ) 8.23 hz, 1h),
7.25 (d, j ) 15.64 hz, 1h), 6.92 (d, j ) 8.23 hz, 1h), 6.65 ( xxxd2595xxx ,
1h), 6.21 (ddd, j ) 15.40, 6.90, 6.79 hz, 1h), 3.18 ( xxxd2595xxx , 6h), 2.61
( xxxd2595xxx , 6h), 1.64 ( xxxd2595xxx , 4h), 1.20 (t, j ) 7.27 hz, 6h). anal.
(c25h32n2o4s‚tfa) c, h, n.

sheppard et al.

2-[({2-[(1e)-5-(diethylamino)-1-pentenyl]phenyl}sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid (25c).
the title compound was prepared from 17a and n,n-diethyl-n[(4e)-5-(tributylstannyl)-4-pentenyl]amine according to method i.
ms (esi(+))  xxxd2595xxx /e 471 ( xxxd2595xxx  + h)+; ms (esi(-))  xxxd2595xxx /e 469 ( xxxd2595xxx  h)-; 1h nmr (400 mhz, dmso-d6) delta 7.93 ( xxxd2595xxx , 1h), 7.57 ( xxxd2595xxx ,
1h), 7.51 (t, j ) 6.97 hz, 1h), 7.35 ( xxxd2595xxx , 1h), 7.17 (d, j ) 15.89
hz, 1h), 7.11 (d, j ) 8.31 hz, 1h), 6.81 ( xxxd2595xxx , 1h), 6.30 ( xxxd2595xxx , 1h),
3.05 ( xxxd2595xxx , 6h), 2.86 (s, 2h), 2.55 (s, 2h), 2.28 (q, j ) 6.11 hz,
2h), 2.01 (s, 2h), 1.55 ( xxxd2595xxx , 4h), 1.21 (t, j ) 6.72 hz, 6h). anal.
(c26h34n2o4s‚hcl‚h2o) c, h, n.
methyl 2-(n-(2-trimethylsilylethoxymethyl)-{[2-bromophenyl]sulfonyl}amino)-5,6,7,8-tetrahydro-1-naphthalene-carboxylate
(26a). to a suspension of nah (60% in  xxxd2648xxx , 1.5 g, 37.5
mmol) in 120 ml of thf was added 17a (12.7 g, 30 mmol) in
portions. after gas evolution was complete, sem-cl (6.6 ml, 37.5
mmol) was added over 5 min. after 105 min, the reaction was
quenched by the addition of 5 ml of 5% aqueous nahco3. the
reaction was then diluted with 300 ml of 5% aqueous nahco3,
and extracted twice with 300 ml etoac. the combined organic
layers were washed with 250 ml of 10% aqueous nacl (backwashed with 200 ml etoac), and the combined etoac layers were
dried over  xxxd2534xxx , filtered, and concentrated. the residue was
chased twice with heptane, and then to the resulting slurry was
added 80 ml of heptane. the solids were isolated by filtration and
washed with an additional 25 ml of heptane. following drying in
vacuo at 35 °c, 16 g (96%) of the product was isolated. ms
(esi(+))  xxxd2595xxx /e 571 ( xxxd2595xxx  + nh4)+; 1h nmr (400 mhz, cdcl3) delta
7.83 (dd, j ) 7.82, 1.92 hz, 1 h), 7.71 (dd, j ) 7.75, 1.30 hz,
1 h), 7.36 (td, j ) 7.55, 1.92 hz, 1 h), 7.31 (td, j ) 7.55,
1.51 hz, 1 h), 7.17 (d, j ) 8.24 hz, 1 h), 7.09 (d, j ) 8.23 hz,
1 h), 5.27 (s, 1 h), 3.71 ( xxxd2595xxx , 2 h), 3.66 (s, 3 h), 2.75 (t, j )
5.83 hz, 2 h), 2.51 (s, 2 h), 1.72 ( xxxd2595xxx , 4 h), 0.94 ( xxxd2595xxx , 2 h), 0.02 (s,
9 h).
methyl 2-(n-(2-trimethylsilylethoxymethyl)-{[2-bromo-4fluorophenyl]sulfonyl}amino)-5,6,7,8-tetrahydro-1-naphthalenecarboxylate (26b). to a suspension of nah (60% in  xxxd2648xxx ,
4.90 g, 122.5 mmol) in 325 ml of thf was added 17b (43.33 g,
98.97 mmol) in portions. after 30 min, sem-cl (21.6 ml, 122.5
mmol) was added over 5 min. after 45 min, the reaction was
quenched by the slow addition of 350 ml of 5% aqueous nahco3.
the reaction was then extracted with 350 ml of etoac. the organic
layers were washed with 250 ml of 10% aqueous nacl, dried over
 xxxd2534xxx , filtered, and concentrated. the residue was triturated with
600 ml of hexanes and the solids isolated by filtration. the filtrate
was concentrated and the residues dissolved in a minimum amount
of etoac, and then diluted with 150 ml of hexanes. the precipitate
was collected and the solids combined to provide 46.14 g (82%)
of the title compound. ms (esi(+))  xxxd2595xxx /e 574, 572 ( xxxd2595xxx  + h)+; 1h
nmr (300 mhz, dmso-d6) delta 7.91 (dd, 1 h), 7.75 (dd, 1 h), 7.36
(td, 1 h), 7.22 (d, 1 h), 7.14 (d, 1 h), 3.62 (bd s, 5 h), 3.31 (s, 2
h), 2.74 ( xxxd2595xxx , 4 h), 2.35 ( xxxd2595xxx , 2 h), 1.67 ( xxxd2595xxx , 4 h), 0.86 ( xxxd2595xxx , 2 h),
0.01 (s, 9 h).
methyl 2-(n-(2-trimethylsilylethoxymethyl)-{[2-((z)-3-hydroxyprop-1-enyl)phenyl]sulfonyl}amino)-5,6,7,8-tetrahydro-1-naphthalene-carboxylate (27a). a flask containing 26a (10 g, 18 mmol)
and pd(pt-bu3)2 (0.92 g, 1.8 mmol) was purged with n2, then 72
ml of degassed (n2) toluene was added, followed by (z)-tributyl(3-hydroxy-prop-1-enyl)stannane28 (7.5 g, 21.6 mmol). the reaction
was heated to 50 °c for 2 h and allowed to cool to ambient
temperature. the product solution was loaded directly onto a silica
gel column and eluted with 30%:60% etoac/hexanes to provide
5.7 g (60%) of the product. ms (esi(+))  xxxd2595xxx /e 549 ( xxxd2595xxx  + nh4)+;
1h nmr (400 mhz, cdcl ) delta 7.81 (dd, j ) 7.96, 1.24 hz, 1 h),
3
7.49 (td, j ) 7.55, 1.37 hz, 1 h), 7.32 (td, j ) 7.72, 1.30 hz, 1
h), 7.20 (d, j ) 7.00 hz, 1 h), 7.03 (d, j ) 8.23 hz, 1 h), 6.98
(d, j ) 11.53 hz, 1 h), 6.87 (d, j ) 8.23 hz, 1 h), 5.96 (dt, j )
11.56, 6.98 hz, 1 h), 5.12 (s, 1 h), 4.14 (d, j ) 7.00 hz, 2 h),
3.64 (s, 3 h), 3.40-3.56 ( xxxd2595xxx , 2 h), 2.71-2.82 ( xxxd2595xxx , 2 h), 2.63 (s, 2
h), 2.05 (s, 1 h), 1.68-1.81 ( xxxd2595xxx , 4 h), 0.78-0.90 ( xxxd2595xxx , 3 h), -0.05
(s, 9 h).

 xxxd189xxx  sulfonamide  xxxg1400xxx  inhibitors

methyl 2-(n-(2-trimethylsilylethoxymethyl)-{[2-((z)-3-hydroxyprop-1-enyl)-4-fluorophenyl]sulfonyl}amino)-5,6,7,8-tetrahydro1-naphthalene-carboxylate (27b). a 50 ml microwave reaction
vessel containing 26b (5.73 g, 10 mmol), pd(pt-bu3)2 (0.558 g,
0.7 mmol), and (z)-tributyl-(3-hydroxy-prop-1-enyl)stannane28 (4.11
g, 11 mmol) in dmf (30 ml) was heated to 150 °c for 10 min
and allowed to cool to ambient temperature. the solution was
diluted with etoac, shaken with brine, filtered through celite,
washed again with brine, and then dried over  xxxd2534xxx . chromatography on silica gel, eluting with 10%:20% etoac/hexanes
provided 5.44 g (99%) of the product. ms (esi(+))  xxxd2595xxx /e 567 ( xxxd2595xxx  +
nh4)+, 572 ( xxxd2595xxx  + na)+; 1h nmr (400 mhz, cdcl3) delta 7.81 (dd,
j ) 7.96, 1.24 hz, 1 h), 7.49 (td, j ) 7.55, 1.37 hz, 1 h), 7.32
(td, j ) 7.72, 1.30 hz, 1 h), 7.20 (d, j ) 7.00 hz, 1 h), 7.03 (d,
j ) 8.23 hz, 1 h), 6.98 (d, j ) 11.53 hz, 1 h), 6.87 (d, j ) 8.23
hz, 1 h), 5.96 (dt, j ) 11.56, 6.98 hz, 1 h), 5.12 (s, 1 h), 4.14 (d,
j ) 7.00 hz, 2 h), 3.64 (s, 3 h), 3.40-3.56 ( xxxd2595xxx , 2 h), 2.71-2.82
( xxxd2595xxx , 2 h), 2.63 (s, 2 h), 2.05 (s, 1 h), 1.68-1.81 ( xxxd2595xxx , 4 h), 0.780.90 ( xxxd2595xxx , 3 h), -0.05 (s, 9 h).
allylic amine synthesis. method j. 2-[({2-[(1z)-3-(dimethylamino)-1-propenyl]phenyl}sulfonyl)amino]-5,6,7,8-tetrahydro-1naphthalenecarboxylic acid (24m). to a solution of 1 mmol of
27a in 5 ml of ch2cl2 in an ice/water bath was added i-pr2net
(0.40 ml, 2.3 mmol) and then mscl (0.09 ml, 1.15 mmol). after
75 min, 2.5 ml of a 2  xxxd2595xxx  solution of dimethylamine in toluene (5
mmol) was added and the reaction warmed to ambient temperature,
diluted with ch2cl2, and washed with 10% aqueous nacl. the
ch2cl2 layer was dried over  xxxd2534xxx , filtered, and concentrated in
vacuo. the product was purified by silica gel chromatography to
yield 457 mg (82%) of the sem-protected methyl ester. ms (esi(+))  xxxd2595xxx /e 559 ( xxxd2595xxx  + h)+; 1h nmr (400 mhz, cdcl3) delta 7.79 ( xxxd2595xxx ,
1 h), 7.48 ( xxxd2595xxx , 1 h), 7.27 ( xxxd2595xxx , 2 h), 7.02 (d, j ) 8.23 hz, 1 h),
6.94 (d, j ) 8.23 hz, 1 h), 6.84 (d, j ) 11.66 hz, 1 h), 5.84 (dt,
j ) 11.73, 6.83 hz, 1 h), 5.09 (s, 2 h), 3.64 (s, 3 h), 3.57 ( xxxd2595xxx , 2
h), 3.00 (dd, j ) 6.79, 1.30 hz, 2 h), 2.74 (t, j ) 5.28 hz, 2 h),
2.61 (s, 2 h), 2.23 (s, 6 h), 1.72 ( xxxd2595xxx , 4 h), 0.88 (dd, j ) 9.06, 7.68
hz, 2 h), -0.02 (s, 9 h).
the intermediate (0.41 g, 0.7 mmol) and lithium iodide (0.28 g,
2.1 mmol) in pyridine (7 ml) were heated in a microwave reactor
at 150 °c for 40 min and then concentrated in vacuo. the crude
product was purified by c18 reverse-phase hplc using acetonitrile/
water/0.1% tfa to provide 24m (0.182 g, 49%). ms (esi(+))
 xxxd2595xxx /e 415 ( xxxd2595xxx  + h)+; 1h nmr (400 mhz, dmso-d6) delta 9.84 (s, 1
h), 9.71 (s, 1 h), 7.79 (d, j ) 7.96 hz, 1 h), 7.66 (t, j ) 7.34 hz,
1 h), 7.50 (t, j ) 7.68 hz, 1 h), 7.30 (d, j ) 8.64 hz, 2 h), 6.96
(d, j ) 8.51 hz, 1 h), 6.62 (d, j ) 8.23 hz, 1 h), 5.86 (dt, j )
11.80, 6.86 hz, 1 h), 3.82 (d, j ) 6.45 hz, 2 h), 2.68 (s, 6 h),
2.61 ( xxxd2595xxx , 4 h), 1.65 ( xxxd2595xxx , 4 h). anal. (c22h26n2o4s‚1.5 tfa) c, h,
n.
2-[({2-[(1z)-3-(1-pyrrolidinyl)-1-propenyl]phenyl}sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid (24i).
the title compound was prepared from 27a and pyrrolidine using
method j. ms (esi(+))  xxxd2595xxx /e 441 ( xxxd2595xxx  + h)+; 1h nmr (400 mhz,
dmso-d6) delta 10.25 (s, 1 h), 9.72 (s, 1 h), 7.79 (dd, j ) 7.82, 0.96
hz, 1 h), 7.65 (td, j ) 7.55, 1.10 hz, 1 h), 7.49 (t, j ) 7.68 hz,
1 h), 7.32 (d, j ) 7.41 hz, 1 h), 7.26 (d, j ) 11.66 hz, 1 h), 6.97
(d, j ) 8.23 hz, 1 h), 6.68 (d, j ) 8.23 hz, 1 h), 5.89 (dt, j )
11.70, 6.84 hz, 1 h), 3.88 (d, j ) 6.45 hz, 2 h), 3.42 (s, 2 h),
2.92 (s, 2 h), 2.64 (s, 4 h), 1.83 (s, 4 h), 1.65 ( xxxd2595xxx , 4 h). anal.
(c25h30n2o4s‚1.4 tfa) c, h, n.
2-[({2-[(1z)-3-(1-pyrrolidinyl)-1-propenyl]-4-fluorophenyl}sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid
(24j). the title compound was prepared from 27b and pyrrolidine
using method j. ms (apci(+))  xxxd2595xxx /e 449 ( xxxd2595xxx  + h)+; 1h nmr (400
mhz, dmso-d6) delta 7.88 (dd, 1 h), 7.25 (d, 1 h), 7.18 (td, 1 h),
7.13 (d, 1 h), 7.06 ( xxxd2595xxx , 2 h), 5.97 ( xxxd2595xxx , 1 h), 3.91 (dd, 2 h), 3.60
( xxxd2595xxx , 2 h), 2.98 ( xxxd2595xxx , 2 h), 2.73 (s, 4 h), 2.00 ( xxxd2595xxx , 4 h), 1.72 ( xxxd2595xxx , 4
h). anal. (c24h27fn2o4s‚tfa) c, h, n.
2-[({2-[(1z)-3-ethyl-3-(2-hydroxyethyl)-1-propenyl]phenyl}sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid
(24k). the title compound was prepared from 27a and n-ethyl-n-

journal of medicinal chemistry, 2006, vol. 49, no. 13 3847

(2-hydroxyethyl)amine using method j. ms (esi(+))  xxxd2595xxx /e 459 ( xxxd2595xxx 
+ h)+; 1h nmr (400 mhz, dmso-d6) delta 9.69 ( xxxd2595xxx , 2 h), 7.80 (dd,
j ) 7.82, 1.10 hz, 1 h), 7.65 (td, j ) 7.51, 1.03 hz, 1 h), 7.50 (t,
j ) 7.27 hz, 1 h); 7.35 (d, j ) 7.55 hz, 1 h); 7.31 (d, j ) 11.94
hz, 1 h), 6.97 (d, j ) 8.37 hz, 1 h), 6.67 (d, j ) 8.23 hz, 1 h),
5.95 (dt, j ) 11.87, 6.90 hz, 1 h), 3.86 (d, j ) 6.31 hz, 2 h),
3.61 ( xxxd2595xxx , 2 h), 3.10 ( xxxd2595xxx , 4 h), 2.64 (d, j ) 3.02 hz, 4 h), 1.66 ( xxxd2595xxx ,
4 h), 1.01 (t, j ) 7.20 hz, 3 h). anal. (c24h30n2o5s‚tfa‚0.5
h2o) c, h, n.
2-[({2-[(1z)-3-(1-4-methylpiperazinyl)-1-propenyl]phenyl}sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid
(24l). the title compound was prepared from 27a and n-methylpiperazine using method j. ms (esi(+))  xxxd2595xxx /e 470 ( xxxd2595xxx  + h)+; 1h
nmr (400 mhz, dmso-d6) delta 7.80 (d, 1 h), 7.65 ( xxxd2595xxx , 1 h), 7.49
(t, 1 h), 7.36 (d, 1 h), 7.21 (d, 1 h), 6.99 (d, 1 h), 6.67 (d, 1 h),
5.88 ( xxxd2595xxx , 1 h), 3.48 ( xxxd2595xxx , 2h), 3.30-2.85 ( xxxd2595xxx , 8h), 2.79 (s, 3h),
2.67 ( xxxd2595xxx , 4 h), 1.68 ( xxxd2595xxx , 4 h). anal. (c25h31n3o4s‚2 tfa) c, h,
n.
2-[({2-[(1z)-3-(dimethylamino)-1-propenyl]-4-fluorophenyl}sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid
(24n). the title compound was prepared from 27b and dimethylamine using method j. ms (esi(+))  xxxd2595xxx /e 433 ( xxxd2595xxx  + h)+; 1h nmr
(400 mhz, dmso-d6) delta 7.81 (dd, 1 h), 7.35 (dt,1 h), 7.28-7.21
( xxxd2595xxx , 2 h), 7.01 (d, 1 h), 6.69 (d, 1 h), 5.90 ( xxxd2595xxx , 1 h), 3.87 (d, 2 h),
2.70 (s, 6 h), 2.65 ( xxxd2595xxx , 4 h), 1.67 ( xxxd2595xxx , 4 h). anal. (c22h25fn2o4s‚
tfa) c, h, n.
2-[({2-[(1z)-3-(n-ethyl-n-methylamino)-1-propenyl]-phenyl}sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid
(24o). the title compound was prepared from 27b and nmethylethylamine using method j. ms (esi(+))  xxxd2595xxx /e 427 ( xxxd2595xxx  +
h)+; 1h nmr (400 mhz, dmso-d6) delta 7.81 (d, 1 h), 7.68 (t, 1
h), 7.52 (t, 1 h), 7.33 (d, 2 h), 6.98 (d, 1 h), 6.68 (d, 1 h), 5.89
(dt, 1 h), 3.82 (d, 2 h), 3.05 ( xxxd2595xxx , 2h), 2.68 (s, 3 h), 2.65 ( xxxd2595xxx , 4 h),
1.65 ( xxxd2595xxx , 4 h), 1.09 (t, 3h). anal. (c23h28n2o4s‚tfa) c, h, n.
2-[({2-[(1z)-3-(n-2-hydroxyethyl-n-methylamino)-1-propenyl]-phenyl}sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid (24p). the title compound was prepared from 27b
and n-methylethanolamine using method j. ms (esi(+))  xxxd2595xxx /e 445
( xxxd2595xxx  + h)+; 1h nmr (400 mhz, dmso-d6) delta 7.82 (d, 1 h), 7.68
(t, 1 h), 7.52 (t, 1 h), 7.35 (d, 2 h), 6.99 (d, 1 h), 6.66 (d, 1 h),
5.94 (dt, 1 h), 3.87 (d, 2 h), 3.63 ( xxxd2595xxx , 2h), 3.10 ( xxxd2595xxx , 2h), 2.69 (s,
3 h), 2.66 ( xxxd2595xxx , 4 h), 1.67 ( xxxd2595xxx , 4 h). anal. (c23h28n2o5s‚tfa) c,
h, n.
2-[({2-[(1z)-3-(n-(1-methylethyl)-n-methylamino)-1-propenyl]-phenyl}sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid (24q). the title compound was prepared from
27b and n-methylisopropyllamine using method j. ms (esi(+))
 xxxd2595xxx /e 443 ( xxxd2595xxx  + h)+; 1h nmr (400 mhz, dmso-d6) delta 7.80 (d, 1
h), 7.67 (t, 1 h), 7.51 (t, 1 h), 7.35 (d, 2 h), 6.98 (d, 1 h), 6.73
( xxxd2595xxx , 1 h), 5.94 (dt, 1 h), 3.79 (d, 2 h), 3.54 ( xxxd2595xxx , 1 h), 2.66 (s, 3 h),
2.58 ( xxxd2595xxx , 4 h), 1.66 ( xxxd2595xxx , 4 h), 1.09 (d, 6h). anal. (c24h30n2o4s‚
tfa) c, h, n.
method k. 2-[({2-[4-(diethylamino)butyl]phenyl}sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid (28c).
a solution of 17a (848 mg, 2.0 mmol), n,n-diethyl-n-[(3z)-4(tributylstannyl)-3-butenyl]amine (1.10 g, 2.6 mmol), and bis(tritert-butylphosphine)palladium (212 mg, 0.4 mmol) in 4 ml of
degassed toluene was stirred at ambient temperature for 20 h. the
mixture was concentrated and chromatographed on silica (0:15%
triethylamine/etoac) to give 0.95 g of (100%) methyl 2-[({2-[(1e)4-(diethylamino)-1-butenyl]phenyl}sulfonyl)-amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylate. 1h nmr (400 mhz, cdcl3) delta
7.85 (d, j ) 7.96 hz, 1h), 7.46 ( xxxd2595xxx , 2h), 7.25 ( xxxd2595xxx , 1h), 7.16 (d, j
) 15.78 hz, 1h), 6.93 (d, j ) 8.20 hz, 1h), 6.84 (d, j ) 8.23 hz,
1h), 6.06 ( xxxd2595xxx , 1h), 5.29 (s, 1h), 3.74 (s, 3h), 2.69 ( xxxd2595xxx , 4h), 2.59
( xxxd2595xxx , 6h), 2.38 ( xxxd2595xxx , 2h), 1.70 ( xxxd2595xxx , 4h), 1.00 (t, j ) 7.14 hz, 6h).
a portion of the product (350 mg, 0.75 mmol) in methanol (12
ml) was hydrogenated with h2 over 90 mg (30 wt %) of 10%
pd/c. after 4.5 h, the reaction was filtered through diatomaceous
earth (celite). the pad was washed with methanol, and the filtrates
were concentrated to provide 332 mg (94%) of methyl 2-[({2-[4-

3848

journal of medicinal chemistry, 2006, vol. 49, no. 13

(diethylamino)butyl]phenyl}sulfonyl)amino]-5,6,7,8-tetrahydro-1naphthalenecarboxylate; ms (esi(+))  xxxd2595xxx /e 473 ( xxxd2595xxx  + h)+; 1h nmr
(400 mhz, cdcl3) delta 7.85 (d, j ) 7.82 hz, 1h), 7.42 (t, j ) 7.14
hz, 1h), 7.30 (d, j ) 7.55 hz, 1h), 7.21 (t, j ) 7.68 hz, 1h),
7.05 (d, j ) 8.37 hz, 1h), 6.99 (d, j ) 8.51 hz, 1h), 3.72 (s, 3h),
2.95 ( xxxd2595xxx , 2h), 2.69 ( xxxd2595xxx , 4h), 2.53 ( xxxd2595xxx , 6h), 1.68 ( xxxd2595xxx , 6h), 1.58 ( xxxd2595xxx ,
2h), 1.00 (t, j ) 7.14 hz, 6h).
the methyl ester (306 mg, 0.65 mmol) and lii (348 mg, 2.6
mmol) in 6 ml of pyridine were heated in a microwave reactor at
150 °c for 35 min and then concentrated in vacuo. the crude
product was purified by c18 reverse-phase hplc using acetonitrile/
water/0.1% tfa to provide 28c (210 mg, 71% yield). ms (esi(+))  xxxd2595xxx /e 459 ( xxxd2595xxx  + h)+; ms (esi(-))  xxxd2595xxx /e 457 ( xxxd2595xxx  - h)-; 1h
nmr (400 mhz, dmso-d6) delta 9.76 (s, 1h), 9.26 (s, 1h), 7.75
(dd, j ) 8.03, 1.30 hz, 1h), 7.55 (td, j ) 7.55, 1.37 hz, 1h), 7.42
(dd, j ) 7.75, 1.17 hz, 1h), 7.32 (td, j ) 7.65, 1.30 hz, 1h), 6.96
(d, j ) 8.37 hz, 1h), 6.69 (d, j ) 8.37 hz, 1h), 3.09 (q, j ) 7.23
hz, 4h), 3.03 ( xxxd2595xxx , 2h), 2.96 ( xxxd2595xxx , 2h), 2.64 ( xxxd2595xxx , 4h), 1.64 ( xxxd2595xxx , 8h),
1.17 (t, j ) 7.27 hz, 6h). anal. (c25h34n2o4s‚tfa) c, h, n.
2-[({2-[3-(diethylamino)propyl]phenyl}sulfonyl)amino]-5,6,7,8tetrahydro-1-naphthalenecarboxylic acid (28a). the title compound was prepared from 17a and n,n-diethyl-n-[(2e)-3-(tributylstannyl)-2-propenyl]amine according to method k. ms (apci(+))
 xxxd2595xxx /e 445 ( xxxd2595xxx  + h)+; ms (apci(-))  xxxd2595xxx /e 443 ( xxxd2595xxx  - h)-; 1h nmr
(400 mhz, dmso-d6) delta 7.88 (dd, j ) 7.83, 1.22 hz, 1h), 7.50
( xxxd2595xxx , 1h), 7.40 (d, j ) 7.58 hz, 1h), 7.29 ( xxxd2595xxx , 2h), 6.85 (d, j )
8.31 hz, 1h), 3.01 ( xxxd2595xxx , 8h), 2.84 ( xxxd2595xxx , 2h), 2.57 ( xxxd2595xxx , 2h), 1.75 ( xxxd2595xxx ,
2h), 1.57 ( xxxd2595xxx , 4h), 1.18 (t, j ) 7.21 hz, 6h). anal. (c24h32n2o4s‚
tfa) c, h, n.
2-[({2-[3-(diethylamino)propyl]-4-fluorophenyl}sulfonyl)amino]-5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid (28b).
the title compound was prepared from 17b and n,n-diethyl-n[(2e)-3-(tributylstannyl)-2-propenyl]amine according to method k.
ms (esi(+))  xxxd2595xxx /e 463 ( xxxd2595xxx  + h)+; 1h nmr (400 mhz, meoh-d4)
delta 7.85 ( xxxd2595xxx , 1h), 7.22 ( xxxd2595xxx , 1h), 7.08-7.05 ( xxxd2595xxx , 3h), 3.22 ( xxxd2595xxx , 4h),
3.18 ( xxxd2595xxx , 1h), 3.06 ( xxxd2595xxx , 1h), 2.93 ( xxxd2595xxx , 2h), 2.74 ( xxxd2595xxx , 4h), 2.02 ( xxxd2595xxx ,
2h), 1.74 ( xxxd2595xxx , 4h), 1.31 (t, 6h). anal. (c24h31fn2o4s‚tfa) c, h,
n.
2-[({2-[5-(diethylamino)pentyl]phenyl}sulfonyl)amino]-5,6,7,8tetrahydro-1-naphthalenecarboxylic acid (28d). the compound
was prepared from 17a and n,n-diethyl-n-[(4e)-5-(tributylstannyl)4-pentenyl]amine according to method k. ms (esi(+))  xxxd2595xxx /e 473
( xxxd2595xxx  + h)+; ms (esi(-))  xxxd2595xxx /e 471 ( xxxd2595xxx  - h)-; 1h nmr (400 mhz,
dmso-d6) delta 10.31 (s, 1h), 7.79 (d, j ) 7.83 hz, 1h), 7.53 (t, j
) 7.58 hz, 1h), 7.42 (d, j ) 7.58 hz, 1h), 7.32 (t, j ) 7.58 hz,
1h), 6.94 (d, j ) 8.31 hz, 1h), 6.81 (d, j ) 8.07 hz, 1h), 4.09 (s,
1h), 3.08 (q, j ) 7.25 hz, 4h), 2.96 ( xxxd2595xxx , 4h), 2.70 (s, 2h), 2.62
(s, 2h), 1.66 ( xxxd2595xxx , 8h), 1.41 ( xxxd2595xxx , 2h), 1.19 (t, j ) 7.21 hz, 6h).
anal. (c26h36n2oss‚hcl) c, h, n.
2-[({2-[3-(dimethylamino)propyl]phenyl}sulfonyl)amino]5,6,7,8-tetrahydro-1-naphthalenecarboxylic acid (28e). the title
compound was prepared from 17a and n,n-dimethyl-n-[(2e)-3(tributylstannyl)-2-propenyl]amine according to method k. ms
(esi(+))  xxxd2595xxx /e 417 ( xxxd2595xxx  + h)+; 1h nmr (400 mhz, meoh-d4) 1h
nmr (400 mhz, dmso-d6) delta 7.77 (d, 1h), 7.60 (t, 1h), 7.47 (d,
1h), 7.36 (t, 1h), 6.98 (d, 1h), 6.72 (d, 1h), 3.13 ( xxxd2595xxx , 2h), 2.98
( xxxd2595xxx , 2h), 2.78 (s, 6h), 2.66 ( xxxd2595xxx , 4h), 1.93 ( xxxd2595xxx , 2h), 1.65 ( xxxd2595xxx , 4h).
anal. (c22h28n2o4s‚tfa) c, h, n.
methyl 2-[(2-bromo-4-fluoro-benzenesulfonyl)-(2-methoxyethoxymethyl)-amino]-5,6,7,8-tetrahydronaphthalene-1-carboxylate (29). to a 25 ml three-neck flask equipped with a mechanical
stirrer, a j-kem temperature probe, and a dry nitrogen line was
charged 17b (3.34 g, 7.55 mmol) in 32 ml of dry thf. to this
mixture was slowly added 60% sodium hydride dispersion (0.44
g, 11.0 mmol). once the foaming subsided, a solution of mem-cl
(1.24 g, 9.95 mmol) in 8 ml of thf was added, and the mixture
was stirred at room temperature overnight. the following morning
the crude reaction mixture was adsorbed onto 16 g of flash grade
silica and purified on a short flash column with 20% ethyl acetate
in hexanes. pooling fractions yielded 3.50 g of pure product as an
off white solid (87.5% yield). ms (esi( xxxd2595xxx  + nh4)+)  xxxd2595xxx /e 548; 1h

sheppard et al.

nmr (400 mhz, cdcl3) delta 7.81 (dd, j ) 8.85, 5.83 hz, 1h), 7.44
(dd, j ) 8.03, 2.54 hz, 1h), 7.21 (d, j ) 8.23 hz, 1h), 7.10 (d, j
) 8.37 hz, 1h), 6.99 (ddd, j ) 8.92 7.55, 2.47 hz, 1h), 3.85 (s,
2h), 3.67 (s, 3h), 3.56 (t, j ) 4.60 hz, 2h), 3.36 (s, 3h), 2.74 (t,
j ) 5.56 hz, 2h), 2.49 (s, 2h), 165-176 ( xxxd2595xxx , 4h).
methyl 2-[[4-fluoro-2-(2-hydroxymethyl-cyclopropyl)-benzenesulfonyl]-(2-methoxy-ethoxymethyl)-amino]-5,6,7,8-tetrahydronaphthalene-1-carboxylate (30). to a 50 ml three-neck roundbottomed flask equipped with a heating mantle, a j-kem temperature
controller, and a dry nitrogen line was charged 29 (1.02 g, 1.923
mmol), bis-tri-tert-butylphosphine palladium (0.099 g, 0.194 mmol),
pd2(dba)3 (0.057 g, 0.62 mmol), and 9 ml of degassed toluene. to
this mixture was added, via syringe, a solution of (2- xxxd3421xxx -cyclopropyl)-methanol28 in 0.5 ml of degassed toluene. the
reaction was warmed to 90 °c and stirred at this temperature
overnight. the following day, the reaction mixture was purified
by flash chromatography (10% ethyl acetate in hexane) to yield
514 mg (52.7%) of product as an oil. ms (esi( xxxd2595xxx  + h)+)  xxxd2595xxx /e 522;
1h nmr (400 mhz, cdcl ) delta 7.75 (dd, j ) 8.85, 5.83 hz, 1h),
3
7.03 (q, j ) 8.14 hz, 2h), 6.96 (dd, j ) 9.88, 2.61 hz, 1h), 6.86
(ddd, j ) 8.82, 7.72, 2.68 hz, 1h), 3.73 (s, 2h), 3.64 (s,3h), 3.51
(t, j ) 4.67 hz, 2h), 3.34 (s, 3h), 2.67-2.77 ( xxxd2595xxx , 4h), 2.59 (s,
1h), 1.73 (s, 4h), 1.49-1.61 ( xxxd2595xxx , 3h), 1.30-1.39 ( xxxd2595xxx , 3h), 0.90 (t,
j ) 7.34 hz, 4h).
method l. 2-[2-(2-diethylaminomethyl-cyclopropyl)-4-fluorobenzenesulfonylamino]-5,6,7,8-tetrahydronaphthalene-1-carboxylic acid (32a). to a 25 ml three-neck round-bottomed flask
equipped with a magnetic stirrer, a heating mantle, a j-kem
temperature controller, a reflux condenser, and a dry nitrogen line
was added 30 (0.248 g, 0.48 mmol) and 1 ml of pyridine. after
mixing to dissolve, mesyl chloride (0.131 g, 1.14 mmol) was added,
and the reaction was monitored by hplc. after 4.6 h, the starting
material was consumed, and the reaction was concentrated under a
stream of dry nitrogen. the residue was dissolved in 3 ml of
diethylamine and heated under reflux for 5 h. after concentrating the crude product, it was purified by flash chromatography
(silica, 5% methanol in methylene chloride) to provide 31a (0.244
g, 89%). ms (esi( xxxd2595xxx  + h)+)  xxxd2595xxx /e 577; 1h nmr (400 mhz,
methanol-d4) delta 7.18 (dd, j ) 10.02, 2.61 hz, 1h), 7.09 (dd, j )
8.30, 2.40 hz, 2h), 4.84 (s, 6h), 3.70 (s, 3h), 3.46-3.53 ( xxxd2595xxx , 8h),
3.13 (q, j ) 7.41 hz, 4h), 2.74-2.81 ( xxxd2595xxx , 2h), 2.22 (d, j ) 13.58
hz, 1h), 1.75 (s, 3h), 1.33-1.42 ( xxxd2595xxx , 2h), 1.17 (t, j ) 7.27 hz,
6h).
a mixture of 31a (0.220 g, 0.419 mmol) and lii (0.165 g, 1.2
mmol) in dry pyridine (4.2 ml) was heated in a microwave reactor
at 160 °c for 25 min. the crude product was concentrated to a
thick oil by drying under a stream of dry nitrogen and then purified
by flash chromatography (silica, 5% methanol in methylene
chloride). the purified product (114 mg, 57%) was then treated
with excess trifluoroacetic acid in methylene chloride to provide
32a as the tfa salt. ms (esi( xxxd2595xxx  + h)+)  xxxd2595xxx /e 475; 1h nmr (400
mhz, cdcl3) delta 9.86 (s, 1h), 7.97 (dd, j ) 8.85, 5.69 hz, 1h),
7.14 (d, j ) 8.51 hz, 1h), 6.97-7.02 ( xxxd2595xxx , 2h), 6.92 (dd, j ) 9.61,
2.33 hz, 1h), 3.11 (d, j ) 5.08 hz, 4h), 3.00 (d, j ) 7.00 hz,
1h), 2.83 (s, 2h), 2.68 (s, 2h), 2.17-2.25 ( xxxd2595xxx , 1h), 1.82 (s, 1h),
1.64-1.73 ( xxxd2595xxx , 4h), 1.45 (s, 1h), 1.25-1.28 ( xxxd2595xxx , 1h), 1.19 (dt, j
) 18.49, 7.22, 6 hz, 6h); 13c nmr (100 mhz, cdcl3) delta 165.78,
163.24, 138.63, 135.41 134.24, 132.39, 117.35, 117.23, 114.21,
52.84, 46.99, 46.29, 29.68, 28.66, 23.04, 22.50, 15.46, 8.72, 8.56,
0.40. anal. (c25h31fn2o4s‚tfa) c, h, n.
2-[2-(2-dimethylaminomethyl-cyclopropyl)-4-fluorobenzenesulfonylamino]-5,6,7,8-tetrahydronaphthalene-1-carboxylic acid
(32b). the title compound was prepared from 30 and dimethylamine
according to method l. ms (esi( xxxd2595xxx  + h)+)  xxxd2595xxx /e 447; 1h nmr
(400 mhz, cd3od) delta 7.92 (dd, j ) 8.78, 5.76 hz, 1h), 7.047.15 ( xxxd2595xxx , 4h), 3.30 (dt, j ) 3.09, 1.61 hz, 1h), 3.16 (dd, j ) 13.04,
4.25 hz, 1h), 2.79-2.83( xxxd2595xxx , 7h), 2.70-2.77( xxxd2595xxx , 4h), 2.23 (dd, j
) 13.04, 10.57 hz, 1h), 1.68-1.77 ( xxxd2595xxx , 5h), 1.34-1.45 ( xxxd2595xxx , 2h);
anal. (c23h27fn2o4s‚1.5 tfa‚h2o) c, h, n.

 xxxd189xxx  sulfonamide  xxxg1400xxx  inhibitors

acknowledgment. we thank hugh nellans, dan hoffman,
and tony borre for the rat plasma protein binding measurements.
supporting information available: details of the synthesis
and characterization of the organostannane intermediates used in
the synthesis of compounds 24-25, elemental analysis results for
the test compounds, and biological assay conditions. this material
is available free of charge via the internet at http://pubs.acs.org.

journal of medicinal chemistry, 2006, vol. 49, no. 13 3849

(14)

(15)

references
(1) arfin, s.  xxxd2595xxx .; kendall, r. l.; hall, l.; weaver, l. h.; stewart, a.
e.; matthews, b. w.; bradshaw, r. a. eukaryotic methionyl
aminopeptidases: two classes of cobalt-dependent enzymes. proc.
natl. acad. sci. u.s.a. 1995, 92, 7714-7718.
(2) serero, a.; giglione, c.; sardini, a.; martinez-sanz, j.; meinnel, t.
an unusual peptide deformylase features in the human mitochondrial
n-terminal  xxxd2595xxx  excision pathway. j. biol. chem. 2003, 278,
52953-52963.
(3) bernier, s. g.; taghizadeh, n.; thompson, c. d.; westlin, w. f.;
hannig, g.  xxxd2595xxx  aminopeptidases type i and type ii are
essential to control cell proliferation. j. cell. biochem. 2005, 95,
1191-1203.
(4) kim, s.; lamontagne, k.; sabio,  xxxd2595xxx .; sharma, s.; versace, r. w.;
yusuff, n.; phillips, p. e. depletion of  xxxd2595xxx  aminopeptidase
2 does not alter cell response to  xxxd2166xxx  or bengamides. cancer
res. 2004, 64, 2984-2987.
(5) sin, n.; meng, l.; wang,  xxxd2595xxx . q.; wen, j. j.; bornmann, w. g.; crews,
c.  xxxd2595xxx . the anti-angiogenic agent  xxxd2166xxx  covalently binds and
inhibits the  xxxd2595xxx  aminopeptidase, metap-2. proc. natl. acad.
sci. u.s.a. 1997, 94, 6099-6103.
(6) griffith, e. c.; su, z.; turk, b. e.; chen, s.; chang, y. h.; wu, z.;
biemann, k.; liu, j. o.  xxxd2595xxx  aminopeptidase (type 2) is the
common target for angiogenesis inhibitors  xxxd1330xxx  and  xxxd2800xxx .
chem. biol. 1997, 4, 461-467.
(7) liu, s.; widom, j.; kemp, c. w.; crews, c.  xxxd2595xxx .; clardy, j. structure
of human  xxxd2595xxx  aminopeptidase-2 complexed with  xxxd2166xxx .
science 1998, 282, 1324-1327.
(8) ingber, d. in cancer therapeutics; teicher, b. a. ed.; humana
press: totowa, nj, 1997; pp 283-298.
(9) bernier, s. g.; lazarus, d. d.; clark, e.; doyle, b.; labenski,  xxxd2595xxx .
t.; thompson, c. d.; westlin, w. f.; hannig, g. a  xxxd2595xxx 
aminopeptidase-2 inhibitor, ppi-2458, for the treatment of rheumatoid
arthritis. proc. natl. acad. sci. u.s.a. 2004, 101, 10768-73.
(10) chun, e.; han, c. k.; yoon, j. h.; sim, t. b.; kim, y.-k.; lee,
k.-y. novel inhibitors targeted to  xxxg1400xxx 
( xxxg1400xxx ) strongly inhibit the growth of cancers in xenografted nude
model. int. j. cancer 2005, 114, 124-130.
(11) wang, j.; sheppard, g. s.; lou, p. kawai,  xxxd2595xxx .; bamaung, n. y.;
erickson, s. a.; tucker-garcia, l.; park, c.; bouska, j.; wang, y.c.; frost, d.; tapang, p.; albert, d.; morgan, s.; morowitz,  xxxd2595xxx .;
shusterman, s.; maris, j.  xxxd2595xxx .; lesniewski, r.; henkin, j. tumor
suppression by a rationally designed reversible inhibitor of  xxxd2595xxx 
aminopeptidase-2. cancer res. 2003, 63, 7861-7869.
(12) townin, h.; bair, k. w.; decaprio, j. a.; eck,  xxxd2595xxx . j.; kim, s.; kinder,
f. r.; morollo, a.; mueller, d. r.; schindler, p.; song, h. k.; van
oostrum, j.; versace, r. w.; voshol, h.; wood, j.; zabludoff, s.;
phillips, p. e. proteomics-based target identification: bengamides
as a new class of  xxxd2595xxx  aminopeptidase inhibitors. j. biol. chem.
2003, 278, 52964-52971. kinder, f. r.; versace, r. w.; bair, k.
w.; bontempo, j.  xxxd2595xxx .; cesarz, d.; chen, s.; crews, p.; czuchta, a.
 xxxd2595xxx .; jagoe, c. t.; mou, y.; nemzek, r.; phillips, p. e.; tran, l. d.;
wang, r.; weltchek, s.; zabludoff, s. synthesis and antitumor
activity of ester-modified analogues of bengamide b. j. med. chem.
2001, 44, 3692-3699.
(13) qian, j.; voorbach,  xxxd2595xxx . j.; huth, j. r.; coen,  xxxd2595xxx . l.; zhang, h.; ng,
s.-c.; comess, k.  xxxd2595xxx .; petros, a.  xxxd2595xxx .; rosenberg, s. h.; warrior, u.;

(16)
(17)
(18)
(19)

(20)
(21)

(22)
(23)
(24)
(25)
(26)
(27)
(28)

burns, d. j. discovery of novel inhibitors of  xxxg251xxx  using multiple
high-throughput screening platforms. anal. biochem. 2004, 328,
131-138.
wang, j.; sheppard, g. s.; lou, p.; kawai,  xxxd2595xxx .; park, c.; egan, d.;
schneider, a.; bouska. j.; lesniewski, r.; henkin, j. the physiologically relevant metal cofactor for  xxxd2595xxx  aminopeptidase-2
is manganese. biochemistry 2003, 42, 5035-5042.
kawai,  xxxd2595xxx .; bamaung, n. y.; fidanze, s. d.; erickson, s. a.; tedrow,
j. s.; sanders, w. j.; vasudevan, a.; park, c.; hutchins, c.; comess,
k.  xxxd2595xxx .; kalvin, d.; wang, j.; zhang, q.; lou, p.; tucker-garcia, l.;
bouska, j.; bell, r. l.; lesniewski, r.; henkin, j.; sheppard, g. s.
development of sulfonamide compounds as potent  xxxd2595xxx 
aminopeptidase type ii inhibitors with antiproliferative properties.
bioorg. med. chem. lett. 2006, 16, 3574-3577.
carter, d. c.; ho, j. x. structure of  xxxg124xxx . adv. protein
chem. 1994, 45, 152-203.
sudlow, g.; birkett, d. j.; wade, d. n. characterization of two
specific drug binding sites on human  xxxg124xxx . mol. pharmacol.
1975, 11, 824-832.
mao, h.; hajduk, p. j.; craig, r.; bell, r.; borre, t.; fesik, s. w.
rational design of  xxxd1882xxx  analogues with reduced affinity for
human  xxxg124xxx . j. am. chem. soc. 2001, 123, 10429-10435.
curry, s.; mandelkow, h.; brick, p.; franks, n. crystal structure of
human  xxxg124xxx  complexed with fatty acid reveals an asymmetric distribution of binding sites. nat. struct. biol. 1998, 5, 827835.
herve, f.; urien, s.; albengres, e.; duche, j. c.; tillement, j. drug
binding in plasma. a summary of recent trends in the study of drug
and hormone binding. clin. pharmacokinet. 1994, 26, 44-58.
oltersdorf, t.; elmore, s. w.; shoemaker, a. r.; armstrong, r. c.;
augeri, d. j.; belli, b. a.; bruncko,  xxxd2595xxx .; deckwerth, t. l.; dinges,
j.; hajduk, p. j.; joseph,  xxxd2595xxx . k.; kitada, s.; korsmeyer, s. j.; kunzer,
a. r.; letai, a.; li, c.; mitten,  xxxd2595xxx . j.; nettesheim, d. g.; ng, s.-c.;
nummer, p.  xxxd2595xxx .; o’connor, j.  xxxd2595xxx .; oleksijew, a.; petros, a.  xxxd2595xxx .; reed,
j. c.; shen, w.; tahir, s. k.; thompson, c. b.; tomaselli, k. j.;
wang, b.; wendt,  xxxd2595xxx . d.; zhang, h.; fesik, s. w.; rosenberg, s. h.
an inhibitor of bcl-2 family proteins induces regression of solid
tumors. nature 2005, 435, 677-681. wendt,  xxxd2595xxx . d.; shen, w.;
kunzer, a.; mcclellan, w. j.; bruncko,  xxxd2595xxx .; oost, t. k.; ding, h.;
joseph,  xxxd2595xxx . k.; zhang, h.; nimmer, p.  xxxd2595xxx .; ng, s.-c.; shoemaker,
a. r.; petros, a.  xxxd2595xxx .; oleksijew, a.; marsh, k.; bauch, j.; oltersdorf,
t.; belli, b. a.; martineau, d.; fesik, s. w.; rosenberg, s. h.;
ellmore, s. w. discovery and structure-activity relationship of
antagonists of b-cell lymphoma 2 family proteins with chemopotentiation activity in vitro and in vivo. j. med. chem. 2006, 49, 11651181.
wolfe, j. p.; ahman, j.; sadighi, r. a.; singer, r. a.; buchwald, s.
l. an ammonia equivalent for the palladium-catalyzed amination of
aryl halides and triflates. tetrahedron lett. 1997, 38, 6367-6370.
wang, j.; lou, p.; henkin, j. selective inhibition of endothelial cell
proliferation by  xxxd2166xxx  is not due to differential expression of
 xxxd2595xxx  aminopeptidases. j. cell. biochem. 2000, 77, 465-473.
mao, h.; gunasekera, a. h.; fesik, s. w. expression, refolding,
and isotopic labeling of human  xxxg124xxx  domains for nmr
spectroscopy. protein expression purif. 2000, 20, 492-499.
fesik, s. w.; zuiderweg, e. r. p. heteronuclear three-dimensional
nmr spectroscopy. a strategy for the simplification of homonuclear
two-dimensional nmr spectra. j. magn. reson. 1988, 78, 588-593.
cavanagh, j.; fairbrother, w. j.; palmer, a. g.; skelton, n. j. protein
nmr spectroscopy. principles and practice; academic press: san
diego, ca, 1996.
brunger, a. t. x-plor version 3.1.; yale university press: new
haven, ct, 1992.
corey, e. j.; eckrich, t.  xxxd2595xxx . a method for the stereospecific synthesis
of chiral cis-2-alkylcyclopropyllithium reagents. tetrahedron lett.
1984, 25, 2415-2418.

jm0601001

